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SUMMARY
Type 2 diabetes is a heterogeneous condition characterized by elevated plasma
glucose levels caused by a combination of insulin resistance and defective
insulin secretion. As for type 1 diabetes, type 2 diabetes is increasingly being
considered to be a disease of reduced -cell mass. The paffiogenic
mechanisms causmg f3-celt loss in type 2 diabetes, however, are poorly
understood. Many studies have indicated that elevated circulatmg free fafty
acids (ffA) contribute to the undertymg pathophysiotogy of the disease and
that fFA represent a crucial link between msulm resistance and f-cell
dysfunction. We previously proposed the “glucolipotoxicity” hypothesis in
which elevated free fatty acids (FFA) together with hyperglycemia are
synergistic in causing istet [3-celi damage because high glucose inhibits fat
oxidation and consequently lipid detoxification. The effects of l-2 days
culture of rat INS $32/13 [3-ceils was investigated in medium containing
glucose (5,11, 20 mM) in the presence or absence of various FfA (0.25-0.4
mM) on pancreatic B-cetl death. A marked synergistic effect of elevated
concentrations of glucose and saturated FfA (palmitate and stearate) on
inducing (3-celi death was fowid in 1NS $32/13 ceils. In comparison, linoleate
(polyunsaturated) synergized only modestly with high glucose, whereas oteate
(monounsaturated) was flot toxic. In INS $32/13 celis, the combination of
elevated glucose and saturated fFA causcd an increase in DNA condensation
and the activity of caspase-3 indicating apoptosis. The pan-caspase inhibitor
z-VAD-fMK reduced ceit death induceil by high glucose but not elevated
glucose together with FFA, due to a switch from apoptosis to necrosis.
Treating ceils with the acyl-CoA synthase inhibitor friacsin C curtailed
glucolipotoxicity. In çontrast, the fat oxidation inhibitor etomoxir enhanced
palmitate-induced ccli deaffi such that, at Iow glucose wiffi palmitate, the same
level of cd death occurred as in the condition of etevated glucose and
palmitate wiffiout the inhibitor. The data indicate that fFA must be
metabolized to LC-CoA to exert toxicity, the effect ofwhich can be enhanced
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by inhibiting fatty acid oxidation. Ceramide levels were increased after
treatment with palmitate but only at elevated levels of glucose. Treatmg ceils
with fumonisin BI or myriocin, both inhibitors of de novo ceramide synthesis,
did flot protect ceils from palmitate-induced ccli death suggestmg that the
action of FFA to promote B-ceIl apoptosis does flot occur via the de novo
synthesis of ceramide. The resuits support the glucolipotoxicity bypothesis of
B-cell failure proposing that elevated FfA are particularly toxic in the context
of hyperglycemia. In addition, the veiy divergent effects of saturated versus
mononsaturated fFA on 8-celi apoptosis bas potential dietaiy implications.
Finalty, sfrategies aimed at enhancing fat oxidation to counteract the
mhibitoiy action of glucose might prove useful to protect 8-ceils from
gtucolipotoxicity.
Key Words: Type 2 diabetes, glucolipotoxicity, apoptosis, long chain acyl
CoA, pancreatic 13-cells, -oxidation.
VRESUME
Le diabète de type 2 est une pathologie multifactorielle caractérisée par une
glycémie élevée résultant d’une résistance à I’ insuline des tissus périphériques
et d’une diminution de la sécrétion d’insuline en réponse au glucose des
cellules-[3 pancréatiques. Comme pour le diabète de type I, plusieurs études
ont démontré une réduction du nombre de cellules-f3 lors des autopsies chez
des personnes ayant souffert de diabète de type 2. Les mécanismes
pathogéniques responsables de cette perte de cellules-(3 sont encore mal
compris. Plusieurs études ont indiqué que te taux élevé en acides gras libres
(AGL) circulants, souvent observé chez les diabétiques, contribue à la
pathophysiologie de cette maladie et que les AGL représentent un lien
primordial entre la résistance à l’insuline et la dysfonction des cellules-(3.
Nous avons proposé l’hypothèse de la «glucolipotoxicité» dans laquelle une
synergie entre un haut taux d’AGL et une hyperglycémie induirait les cellules-
(3 pancréatiques à entrer en apoptose. L’induction de I’apoptose serait initiée
par l’action inhibitrice du glucose à haute concentration sur la (3-oxydation des
AGL et par conséquent empêcherait la détoxification lipidique.
Pour étudier cette hypothèse, nous avons utilisé le modèle de cellules-fI de rat
INS 832/13 et recherché les effets sur la mort cellulaire d’un traitement de 1 à
2 jours avec du glucose (5, 11 ou 20 mM) en présence ou absence de
différents AGL (0,25-0,4 mM) couplés à la BSA Un effet synergique du
glucose à concentration élevée et des AGL saturés (palmitate et stéarate) a été
trouvé sur l’apoptose des cellules INS $32/13. Le linoléate (acide gras
polyinsaturé) présentait une faible synergie avec le haut glucose alors que
l’oléate (acide gras monoinsaturé) n’était pas toxique. Dans les cellules INS
832/13, la co-incubation des cellules en présence de concentrations élevées en
glucose et AGL saturés a provoqué des augmentations de la condensation de
l’ADN et de l’activité de la caspase-3, deux phénomènes caractéristiques du
processus de mort cellulaire par apoptose. Le z-VAD-finlç un inhibiteur non
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spécifique des caspases, a réduit la mort cellulaire induite par le haut glucose
mais pas celle provoquée par le co-traitement avec des taux élevés de glucose
et d’AGL Dans ce dernier cas, le z-VAD-fmlç a induit un changement de
type de mort cellulaire, l’apoptose faisant place à la nécrose. Le traitement des
cellules 1NS $32/13 avec la kiacsin C, un inhibiteur de l’acyl-CoA synthase, a
empêché la glucolipotoxicité. Par contre, l’etomoxir, un inhibiteur de la -
oxydation, a accru la mort cellulaire induite par le palmitate. En effet, nous
avons observé les même taux de mort cellulaire à bas glucose en présence de
palmitate et etomoxir qu’à haut glucose plus palmitate sans etomoxir. Ces
résultats indiquent que les AGL doivent être métabolisés en acyl-CoA à
longues chaînes pour exercer leur toxicité et que celle-ci peut être accrue suite
à l’inhibition de la f3-oxydation. Etant donné que plusieurs études ont
démontré l’importance des céramides dans l’initiation de l’apoptose et que les
céramides peuvent être produits à partir d’AGL (synthèse de novo), nous
avons vérifié si les céramides contribuaient à l’initiation de l’apoptose induite
par le palinitate et le haut glucose. Nous avons mesuré des taux élevés en
céramides après incubation des cellules avec du palmitate à haut glucose
seulement. Le traitement des cellules 1NS $32/13 avec la fumonisin BI ou la
myriocin, deux inhibiteurs de la synthèse de novo des céramides, n’a pas
protégé les cellules de la mort cellulaire induite par le pahnitate suggérant que
l’effet pro-apoptotique des AGL n’a pas lieu via la synthèse de novo des
céramides.
Dans leur ensemble, nos résultats appuient l’hypothèse de la glucolipotoxicité
(toxicité de taux élevés d’AGL dans un contexte d’hyperglycémie) comme
étant responsable de la perte en ceI1utes- pancréatiques. finalement, les
effets divergents des acides gras saturés versus les acides gras insaturés sur
l’apoptose des cellules-13 pourraient avoir des implications diététiques.
Finalement, des stratégies visant à accroire la f3-oxydation pour compenser
l’action inhibitrice du glucose pourraient se montrer utiles pour protéger les
cellules-13 de la glucolipotoxicité.
V”
Mots clés: diabètes de type 2, glucolipotoxicité, apoptose, acyl-CoA à
longues chaînes, ce1luIes-3 pancréatiques, r-oxydation.
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CHAPTER I: INTRODUCTION
1. ffiSTORICAL INFORMATION
It is eighty ycars after flic discovery of msulm and we are stiil faced with
many challenges conceming diabetes. Despite tremendous advances in our
knowledge, we do flot understand the accelerated rate of diabetes appearance
in our present time. An improved understanding of flic pathophysiological
basis of diabetes is stii required.
Diabetes Mellitus is a medical condition known to physicians for thousands of
years. References to this disease can be found in many ancient writings. It was
first descnbed on an Egyptian papyrus which was discovered in Egypt in
1862, which is said to have been written between 3000 and 1500 BC. The first
use of the term “Diabetes Mellitus” dates back to the second century AD.
“Diabetes” stems from the Greek word “siphon” for ‘pipe-like’ or flic passing
through of water. ‘Mellitus’ is Latin for ‘honey’ or ‘sweet’ (Halliweli and
Guftendge, 1999).
In the middle of the 1 9’ century, evidence from autopsies startcd to suggest a
link between the pancreas and Diabetes Mellitus. In 1869, a German scientist
called Paul Langerhans discovered the existence oftwo systems ofcells in flic
pancreas: the acinar ceils, secreting the pancreatic juice into the digestive
system, and islets floating between flic acini with, at that tïme, an unknown
function. Several years later, these ceils became known as flic islets of
Langerhans. In I $89 Minkowski and Von Menng gave the first direct
evidence ofthe hnk between diabetes and flic pancreas. They depancreatised a
dog causing a state of polyuria indistinguishable from diabetes. This was
followed by work by many researchers tili flic summer of 1920, when Banting
and Best discovered insulin. On May 3, 1922, the discovery of insulin was
officially announced to the medical community. It took another six years for
2Steiner to establish diat insulin is a protem, and until 1955 for the pnmary
structure of insulin to be elucidated by Sanger and co-workers. (Histoncal
information was obtained from: www.diabetesforum.net www.med.uni
giessen.de; www.diabetes.ca).
2. CLASSIFICATION 0F DIABETES
Diabetes mellitus is in reality, a group of disorders that have in cominon
hyperglycemia resultmg from defects in insulin production, insulin action or
both. A hallmark in understanding die etiology of a disease lies in a proper
classification ami differentiating its varlous fonus depending on varlous
factors. Targeted research, treatment and prevention of diabetes mellitus
depend on an appropnate classification. ‘[bus, die growth of studies on die
epidemiology and public health aspects was necessaly for die field to move
on. This required a new classification of the disease based on die huge
scientific interest. The recent update of die classification of diabetes mellitus
took place in 1997 by die World Heaiffi Orgamzation (WHO) ami die
American Diabetes Association (ADA), which was a revision of die 1985
WHO Study Group (Zimmet 1999). According to titis classification, die
etiological types ofdiabetes are:
2.1 Type 1 Diabetes Meflitus
Type 1 (formerly called insulin-dependent diabetes mellitus, IDDM) is an
autoimmune disease in which die (-ce11s of die pancreas are destroyed. In tins
type, insulin is required for survival to prevent ketoacidosis, coma and death.
‘[bis is classically a disease of cbildren and young aduits, but recent studies
indicate that type I diabetes can occur at any age. Genetic determinants such
as HLA type seem important for die onset in many patients, with
environmental factors, possibly viral infection a close second. Type I may
account forS to 10 % of ail diagnosed cases ofdiabetes.
32.2 Type 2 Diabetes Mellitus
Type 2, (fonnerly catled non-insuim dependent diabetes mellitus NIDDM), is
die most common fonu of diabetes. It is characterized by disorders of msulm
resistance and rnsulm secretion, either of which can be the predommant
feature. Bodi disorders are usually present at die time die disease is clinically
manifested. It classically occurs in aduits, especially die elderly, but recently it
is being diagnosed wiffi increasing frequency in chiidren and adolescents. It is
in most instances a polygenic disease, but also very life style dependent. Its
prevalence, like obesity which is a major nsk factor for ils development, is
increasing rapidly particularly in developing counties. Type 2 diabetes wiIl be
discussed in much greater depth later in die introduction.
23 MODY (Matunty Onset Diabetes of the Young)
MODY is a familial condition widi autosomal dominant inheritance. It is a
monogemc form of diabetes charactenzed by early age of onset (< 25 years),
and pancreatic f}-ceII dysfimction. ‘iliere are 6 types of MODY, four of which
are caused by a mutation affecting a transcription factor. MODY 1, 3, 4 and 5
are caused by mutations affecting die transcription factors hepatocyte nuclear
factor HNf-4cz (MODYI), HNF-la (MODY3), pancreatic and duodenal
homeobox protein-1 (PDX-1) (MODY4), HNF-1 (MODY5) and NeuroD/2
(MODY6). HNF regulates die expression of metabolic genes and glucose
transporters whereas PDX-1 is implicated in die development of die pancreas
and die regulation of die insulin gene. MODY2 is caused by a mutation
affectmg die glucokinase gene, die enzyme which catalyzes die rate limiting
step ofglycolysis (Froguel and Vefflo 1999; Wobser, Dussmann et al. 2002).
42.4 Statistics
Many swveys have conftrmed that increasmg urbanization and
indusmalization is associated with an increased prevalence of type 2 diabetes.
The world Heaiffi Organization (WHO) estimates diat, in 1997, 143 million
people (6.2 % of die population) were afflicted wiffi diabetes worldwide. It is
predicted that these numbers will likely double by die year 2020 (O’Rahilly
1997). At home, diabetes is considered as a leading cause of death by disease
in Canada and die number of Canadians afflicted with die disease bas reached
around 2 million people (www.diabetes.ca). Diabetes is one of the most
common afflictions of die aged, but its prevaience, pafticularly of type 2
diabetes is rapidly increasing in younger individuals usually in association
wiffi obesity (Bramblett, Huang et al. 2000).
2.5 Burden ofDiabetes for Affected Individuals
The long terni complications of diabetes are divided lute die microvascular
complications, affecting die eye, kidney and nervous system, and die
macrovascular complications with accelerated atherosclerosis and increased
nsk of amputation, myocardial infarction and stroke. Diabetes is considered to
be die leading cause cf ail diese complications, in addition to biochemical
imbalances like ketoacidosis. The basic mecharnsms of each of diese
complications is a combrnation cf die adverse effects cf hyperglycemia on
tissues, stimulation of vanous growth factors, and the secondaiy effects of
conditions frequently associated wiffi diabetes such as hypertension and
hyperlipidemia. People wiffi diabetes are also more susceptible to many other
illnesses. In 1999, diabetes was considered to be die sixth leading cause cf
deaffi w die U.S., representing aroimd 19 % of ail deaths (www.ADA.com).
In addition to die healdi issues, diabetes represents another burden, an
economic one, on die individual and on die govemment.
53. GLUCOSE HOMEOSTASIS
The blood glucose level is a balance between glucose absorption from the gut,
glucose production by the liver and glucose utilization by msulm-mdependent
tissues (such as ffie brain, kidney, and erytbrocytes) and insuim-dependent
tissues (such as fat and muscle). This balance is regufated by many
neurohormonal factors including hormones of the endocrine pancreas (insulin
from the -cells and glucagon from the Œ-cells) which have an important
central role (Kahn 1994). Blood glucose level is normally at 5 mM. Insulin
secretion from -cells and glucagon secretion from Œ-cells respond very
precisely to small changes in glucose concentration in the physiologic range,
ffiereby keeping glucose levels within the range of 3.7-7.0 mM in normal
individuats (van Haeften 2002).
3.1 Post Prandial (Fed State)
Glucose, with other nufrients, is absorbed from the intestine into the portai
circulation thus causing a rise in plasma glucose aiid other nutrient levels. The
islet responds to this perturbation in nutrient levels by insulin secretion from
the p-cells (Figure lA). Glucose is the primary nutrient secretagogue for
insulin, but its effectiveness as a secretagogue can be enhanced by other
nutrients such as amino acids, fatty acids and non-nutrient stimuli (incretins)
which are elevated after a mixed meal such as GLP-1 and gastric inhibitory
peptide (GIP) (van Haeften 2002). The resultant increase in circulating insulin
levels stimulate glucose uptake into insulin-sensitive tissues such as skeletal
muscle, heart and adipose tissue and inhibits endogenous glucose production
from the liver and kidney. Glucose utilization by insulin-insensitive tissues,
such as the brain, change minimally after a meal. Thus, insulin causes an
increase in glucose clearance from blood and reduced glucose entiy into blood
with the end effect of returrnng the post-prandial glucose nse back to pre-meal
levels.
63.2 During fasting
During fasting, ffie bram in particular requires a constant supply of glucose.
This of course can flot corne ftom exogenous sources as glucose entry from
the gut will be zero. It must corne from an endogenous supply. Islet hormones
are again instrumental in regulating glucose flux dunng fasting (Figure lB).
Pst-pand:aI During Fasting
Liver &ain Liver Brain
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Figure 1. Glucose homeostasis (A) postprandially and (B) during
fasling. A. After a meal, the intestine will absorb glucose and there
wilI be an increase in plasma glucose levels (> 5.5 mM). The rise in
glucose will stimulate the P-cells of the pancreas to secrete insulin.
Glucose uptake by insulin-insensitive tissues such as brain will
continue. Elevated insulin levels will inhibit endogenous glucose
production from the liver and kidney and will promote storage of
glucose in the liver, muscle and adipocytes. Thus normoglycemia is
restored. B. During fasting, the brain requires a constant supply of
glucose which has to corne from endogenous sources. Glucose levels
fail which results in reduced insulin secretion and increased glucagon
secretion. Glucose uptake by insulin sensitive tissues is consequently
reduced and endogenous glucose production by glucagon stimulation
of gtycogenolysis and gluconeogenesis is increased. Hepatic
glycogenolysis is stimulated ami glucose entry to the muscle and
adipocytes is decreased. Glucose levels are maintained in the range of
4-5 mM (modified from Kahn, 1994).
With falling glucose levels, insulin secretion also falis, such that insulin
effects on stirnulating glucose entry into muscle and fat will be minimal and
CL
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the inhibitory effect on endogenous glucose production will be abrogated.
7Faliing glucose levels also result in the secretion cf glucagon from islet a
celis. Glucagon stimulates endogenous glucose production by promotmg
glycogenolysis and gluconeogenesis. Thus, endogenous glucose production
will increase, and glucose entry mto the muscle and the adipocytes will
decrease (Defronzo 1988). This state resuits in maintenance of
nonnoglycemia (4-5 mM) with provision ofthe essential glucose supply to the
brain.
Dysregulation of glucose homeostasis, whether resulting in elevated blood
glucose (hyperglycemia) or low blood glucose levels (hypoglycemia), will
have defrimental effects on the individual. Hyperglycemia is the hallmark of
diabetes mellitus.
4. L1Pifi HOMEOSTASIS
Lipid, as for glucose homeostasis, is markedly altered between the fed and
fasted states. free fatty acids (FFA) constitute an important energy source in
most body tissues, representing the primary oxidative fuel for liver, resting
skeletal muscle, renal cortex and myocardium (Coppack, Jensen et al. 1994).
FFA also have an important physiological role during pregnancy. During late
pregnancy, lipolytic hormones stimulate fat breakdown, leading to elevations
in plasma FFA concentrations, which induces peripheral insulin resistance and
causes a switch in fuel metabolism from carbohydrate to fat oxidation, thus
maximizing the availability of glucose for the developing foetus (Boden
1996).
4.1 Post-Prandiat (Fed State)
In peripherat tissues, post-prandial nses in insulin promote the accumulation
of triglyceride (TG) storage by the following: Inhibition of hormone sensitive
lipase (HSL) with suppression of lipolysis of tissue TG stores; activation of
8Iipoprotein lipase with hydrolysis of TG withm chylomicrons and VLDL and
transfer of released FFA mto ceils for subsequent esterification and storage,
and activation of lipogenesis pathways.
In die tiver, fatty acid oxidation is inhibited whereas fatty acid estertification
ami synthesis of VLDL is promoted. Lipogenesis from glucose is also
promoted (McGarry and Brown 1997).
4.2 During Fasting
In peripheral tissues, lipolysis of stored TG via HSL is promoted resulting in
increased flux of FFA into the circulation ami increased availability of FFA
for oxidation particularly in heart and skeletal muscle.
In the liver, fafty acid oxidation is increased with the production of ketone
bodies (McGany and Brown 1997).
4.3 Rote of Matonyt-CoA Regulation of Carnitine Palmitoyl Transferase I
Activity in Lipid Homeostasis
The relationship between malonyl-CoA, an intermediate in lipogenesis, and
carnitine palmitoyl transferase I (CPT I), an outer mitochondnal membrane
enzyme which is the rate limiting enzyme in mitochondrial -oxidation of
fatty acids, was first reported in the liver. During states of high insulinllow
glucagon ratio, i.e. with carbohydrate feeding the liver activeIy converts
glucose carbons via malonyl-CoA to fatty acids and then to LC-CoA
(McGarry and Brown 1997). If the newly formed LC-CoAs were to react with
camitine under the influence of CPT I, it would be converted back to acetyl
CoA through the process of -oxidation, thus generating a futile cycle. This
does not happen. however, as the elevated pool of malonyl-CoA produced
from anaplerosis and the acetyl-CoA carboxylase (ACC) reaction during
active lipogenesis inhibits CPI I. The LC-CoA, therefore can react with
glycerol phosphate to form TG which in the liver can be exported in the form
9of VLDL. However, in periods of iow insulinlhigh giucagon, like starvation,
the pathway of fatty acid synthesis cornes to a hait, the rnalonyl-CoA
concentration falis, CPT 1 becornes demhibited and fafty acids reachmg the
liver readily enter the -oxidation paffiway to form ketone bodies.
This interaction between malonyl-CoA and CPI I has been observed to be at
work in a variety of nonhepatic tissues, particularly the heart and skeletal
muscle and the -ce1I as well (Saddilç Gambie et al. 1993; Prentki and Corkey
1996; Saha, Vavvas et ai. 1997; Memil, Kurth et al. 1998). However, in the
non-lipogenic tissues, the metabolic role ofmalonyl-CoA differs.
4.3.1 Matonyl-CoA
Malonyl-CoA is the product of ACC and in the liver as well as in other
lipogenic tissues is the first committed intermediate in the pathway of fatty
acid synthesis. In ail tissues, lipogenic and non-iipogenic, it acquires its
significant regulatory role by inhibiting CPI I, the first step specific to the
opposing process offatty acid oxidation (McGarry and foster 1980; McGarry,
Woeltje et al. 1989). Malonyl-CoA inhibits a class of carnitine
acyltransferases that catalytically have access to the cytosoiic pool(s) of long
chain acyl-CoA esters.
4.3.2 CPTI
Ihe essential role of camitine in the oxidation of long-chain fatty acids by
mammalian tissues first emerged in the mid 1950. The formation of
acylcarnitines enables acyl moieties to cross intraceliular membranes, which
are otherwise impenneable to acyl-CoA esters. This occurs through the action
of specific carnitine/acylcamitme carriers, highly expressed in both
mitochondrial membranes and peroxisomal membranes. Acyl-CoA first reacts
with camitine under the influence of a CPI I on the outer aspect of the
mitochondriai inner membrane, generating free CoA and acylcarnitine.
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Acyicamitme then permeates the limer membrane (possibly via a specific
camer mechanism) and reacts with a matrix pool of CoA in a reaction
catalyzed by CPT 11 on the limer face of the limer membrane. The re-formed
acyl-CoA then enters the pathway of -oxidation, while the released carnitine
retums to the extramitochondnal compartment (McGarry and Brown 1997). In
the liver, CPT I plays a pivotai role in the regufation of fafty acid oxidation
(McGarry, Mannaerts et al. 1977; McGarry, Leatherman et al. 197$).
This metabolic branch point (fatty acid traffic through estenfication on
oxidation) is controlled by malonyl-CoA (McGany and foster 1980;
McGarry, Woeltje et al. 1989). Malonyl-CoA regulation of CPT I appears to
play a cmcially important physiological role in the pancreatic 3-ce1l as is
discussed below in the section on insulin secretion.
5. PANCREAS
5.1 Anatomy of the Pancreas
The pancreas is an elongated, tapered organ (about 22 cm long) tocated across
the back ofthe abdominal cavity (Bramblett, Huang et al. 2000). It is in close
proximity to the duodenum behind the stomach (figure 2).
figure 2. Anatomy of the pancreas. The right side of the organ (called the
head) is the widest part ofthe organ and lies in die curve ofthe duodenum, the
first division of the small intestine. The tapered Ieft side extends slightly
upward (called the body of the pancreas) and ends near the spleen (called the
tau).
jt1-ç 4i.ici
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The structure of the pancreas is dominated by the fact that it is a dual function
organ with both exocrine and endocrine celi types. The vast bu& of the
pancreas is composed of exocrine tissue, and secretions from these cells flow
into a series of ducts for ultimate delivery into the duodenum. Embedded
within this exocrine tissue are roughty one million smalt clusters of cetis
called the Islets of Langerhans. Islets of Langerhais are the endocrine
component of the pancreas. Islets contain several ceil types (Figure 3) and are
richly vascularized. They secrete insulin, glucagon and several other
hormones (Bramblett, Huang et al. 2000).
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figure 3. Islet histotogic image.
A histologie image of an islet which is the large cluster of pale
staining ceils in the middle. Ail of the surrounding tissue is exocrine
tissue.
5.2 Exocrine Pancreas
The exocrine pancreas is composed of acini and ducts which comprises 90 %
of the pancreas. The acini are composed of columnar to pyramidal epithelial
ceils with minimal stroma. The pancreas produces 2 Iiters/day of bicarbonate
nch fluid containing digestive enzymes. The pancreatic enzymes are tiypsin,
chymotiypsin, aminopeptidases, elastases, amylases, lipases, phospholipases
and nucleases.
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53 Endocrine Pancreas
The endocrine pancreas consists of islets of Langerhans which are of
endodermat origin and represents I % offfie pancreas. The size ofeacb islet is
usually 0.1 to 0.2 mm. There are around one million islets per pancreas. The
cellular composition of islets: beta (f1) cells (68 %), alpha (a) cells (20 %),
delta (il) ceils (10 %), PP ceils (2 %) and serotonin ceils (rare).
u-ceNs: secrete glucagon in response to low blood glucose levels which
stimulates die release of glucose from stores thereby restoring blood glucose
levets.
p-cells: secrete insulin in response to high levels of glucose in die blood.
6-celis: secrete die hormone somatostatin (repfcsses the release of insulin and
glucagon).
P? ceNs: secrete pancreatic potypeptide (PP). The rote of PP is not absolutely
clear, but it appears 10 be involved in the regulation of offier isfet hormones
and possïbly food intake.
6. INSULIN
In the fail of 1920, woddng at die University of Toronto, Fred Banting and
Charles Best were able to make a pancreatic extract which had anti-diabetic
characterisfics. This extract was calied insulin which ongmates from die Latin
word “island” (Best 2002).
At diat time Sir Frederick Banting said:
“Insulin is flot a cure, more work needs Ko be done”.
Human insuhn is a peptide hormone contammg 51 amino acids. A single
molecule consists of 2 polypeptide chains commonly labeled A (21 amino
acids) and B (30 amino acids). The chains are linked by two disulfide bridges
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(Kahn 1994). Insulin is secreted by the (3-celis of the pancreas and lias an
important role in metabolism as discussed betow.
6.1 Insuhu Biosynthesis
The pancreatic p-cetl nonnally maintains a stable balance among insulin
secretion, insulin biosynthesis and insulin degradation to keep optimal
intracellular stores of die hormone. lnsuhn biosynffiesis follows die same
pathway as offier peptide hormones (Vander, Shennan et al. 1990). Its
biosynthesis starts in the nucleus of die (3-ceti of die pancreas as a senes of
precursors beginning wiffi pre-proinsulin, die protein encoded in die insulin
gene. These precursors direct die prohormone into die secretory paffiway
ending fmalty in die secretoly granules where it is convefted into insulin and
C-peptide. These products are stored and secreted togedier in a highly
regulated manner in response to glucose and other stimuli (Steiner, Rouille et
al. 1996).
6.2 Insulin Fanction
The actions of die anabolic hormone insulin are multifaceted affecting cellular
metabolism (Kahn 1994; Bmmblett, Huang et al. 2000). Insulin plays an
important rote in many aspects of ceil physiology, however, its most
prominent mie is to stimulate glucose uptake in penpheral tissues after a meal.
Insulin effects have been lmown for quite some time and these include:
• membrane transport ofglucose, amino acids and certain ions;
• incrcased storage of glycogen;
• formation oftriglycerides and other complex Iipids;
• stimulation of DNA, RNA and protein synthesis.
These actions exert wide spectra of regulatory effects on die ceti (I3ramblett,
Huang et al. 2000). They fali mto two categories: metabotic and growth
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promoting effects. Metabolic effects are of short or long (with the
mvolvement of genes) duration on the uptake, transport, mtennediary
metabolism and storage of small food molecules-hexoses, amino acids and
fatty acids. Insulin reduces the leveis of circulating fatty acids, amino acids
and blood glucose levels by promotmg conversion to theif storage forms and
also by inhibiting gluconeogenesis and lipolysis. The growth-promoting
effects of msulm in other words mitogenic, are of long duration and are
realized on the gene level. They mduce expression of a number cf specific
genes, stimulation ofthe synthesis ofDNA, RNA and specific proteins, and as
a resuit the process of ceil growth as a whoie (Fanti, Johnson et al. 1993).
Insulm lias also been shown to suppress apoptosis (Rampalli and Zelenka
1995; Bertrand, Affi et al. 199$; Diaz, Pimentel et al. 1999; Kang, Song et al.
2003).
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Figure 4: Protem phosphorylation is required to mediate msulin
action. After receptor autophosphoiylation, the f3-subunit becomes
active as a tyrosine-specific kinase ami catalyzes phosphoiylation of
several mtracellular proteins. This event provides the underpinning of
the different actions cf insulin which inciude: 1- stimulation cf glucose
turnover by favoring its transport across the plasma membrane; 2-
promoting protein synthesis in almost ail tissues by affecting gene
transcription, messenger RNA translation and amino acid uptake; 3-
increasing DNA synthesis and prevention of apoptosis via its
mitogenic effect; 4- stimulation of ion transport across the plasma
membrane; 5- stimulation of lipid synthesis; and 6- prevention cf
lipolysis by inhibiting hormone sensitive lipase (HSL) (Kahn 2000).
15
Once in the blood, insulm affects glucose homeostasis by stimulatmg the
uptake of glucose mto skeletal muscle and, to a lesser extent, mto liver and
adipose tissue and by inhibiting glucose production from liver or kidney. In
muscle and adipocytes, glucose uptake is mediated by transiocation of the
insulin-sensitive glucose transporter GLUT4 from mtracellular glucose
storage sites to the plasma membrane. Insuim also switches glycogen
metabolism from glycogenolysis to glycogen synthesis in muscle. With
respect to endogenous glucose production, msulin, either directly or as a
consequence of suppressing ffA levels by inhibiting adipocyte lipolysis,
inhibits glycogenolysis and gluconeogenesis. The enzymes involved in the
insulm-regulated processes of glucose metabolism appear to be regulated by
(de)phosphorylation of serine andlor threonine residues.
Ail knowri actions of insulin are initiated at the plasma membrane by insulin
receptors responding to ligand binding. Ligand binding promotes ATP
binding and autophosphoiylation ofthe cytoplasmic tyrosine kinase domain of
the receptor.
The insulin receptor primarily regulates nutritional metabolic pathways,
whereas ail other receptor/tyrosine kinases mainly regulate celi growth and
differentiation. The insulin receptor is a heterodimer consisting of two Œ and
two [I subunits linked by disuiphide bridges. Transduction ofthe insulin signal
includes the following events: (1) binding of hormone with the two
extracellutar a-subunits (135 KDa) of the receptor which performs a ligand
binding function; and leads to (2) activation of receptor tyrosine kinase
activity and autophosphorylation of the two transmembrane -subunits (95
KDa); resuiting in (3) induction of a downstream cascade of tyrosine
phosphoiylation of a wide spectnlm of effector proteins (Pertseva, Shpakov et
al. 2003). The insulin receptor signal transduction, as for other receptors in the
receptor tyrosine kinase family, does not form direct complexes with
substrates andlor effector molecules after autophosphorylation. Instead, the
insulin receptor, upon autophosphoiylation of at ieast the tri-tyrosine
16
subdomam, acquires exogenous kinase activity, phosphorylating its principal
subsfrate: insulin receptor substrate 1 (IRS1). IRSI, in turn, binds effector
molecules which are responsible for the actuat processes of glucose transport,
metabolism and ceil growth (Kahn 1994; Pertseva, Shpakov et al. 2003).
7. INSULIN SECRETION
Insulin secretion from die pancreatic f-cell is a highly regulated process diat
maintains blood glucose levels wiffiin a very narrow range. Glucose
homeostasis is achieved by a complex interplay between nutrients, hormones
and die autonomic neivous system.
7.1 Pancreatk -CeII Secretagogues
Insulin secretion is regulated by many factors such as nutrients and neuro
hormonal agents (Figure 5). The calorigenic agents which stimulate insulin
secretion include glucose, free fatty acids and amino acids such as glutamine
and leucine. Important examples of neurobonuonal agents which stmiubte
insulin secretion include glucagon like peptide-1 (GLP-1), die ‘gastric
inhibitory peptide’ (GIP), glucagon, cholecystokinin (CCK) and acetylcholine.
(Hedeskov 1980; Wollheim and Sharp 1981; Prenfld and Matschinsky 1987).
Neurohormonal agents known to have an inhibitoiy effect on insulin secretion
include somatostatin, galanine and -sympadio-mimetic agents.
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Glucose Somatostatin
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FigureS. Stimubtors and inhibitors of msulin secretion.
The calorigenic nufrients such as (glucose, amino acids and ftee fafty
acids) and certain peptîdes like the incretin GLP-1, the gastrointestinal
inhibitory polypeptide (GIP) and CCK stimulate the secretion of
insulin, whereas somatostatin, galanine and adrenaline inhibit insulin
secretion.
72 Mechanism of Insulin Secretion
Glucose, the primary stimulus for insulin secretion in the -ceIl, elicits a
biphasic insulin secretion. The first phase is sharp, reaches its maximum at 3-5
mm, and lasts approximately 10 min. The second phase is more blunted and
lasts as long as glucose levels remain elevated (Porte and Pupo 1969; Poitout
and Robertson 1996). This biphasic response is believed to be due to two
signaling pathways of glucose-stimulus-secretion coupling. One is the weII
known KATp channet dependent pathway by which glucose depolanzes the 3-
ceil, actïvates voItage-dependent-Ca2 channels, and mises [Ca2’]1. The other
pathway is the less known KATp channel independent pathway (Gembal,
Gilon et al. 1992; Sato, Aizawa et al. 1992; Straub, James et al. 199$).
7.2.1 Calcium and rATP Channel Dependent Pathway
Glucose enters the -cell through a facilitative glucose transporter, GLUT 2,
which allows rapid equitibration between extra- and mtracellular glucose
Insulin
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concentrations. Glucokinase (GK) phosphoiylates glucose to produce glucose-
6-phosphate (G6P). G6P then enters glycolysis producing pyruvate. in the
mitochondria, pyruvate is decarboxylated to generate acetyi-CoA (Ac-C0A)
by the action cf pyruvate dehydrogenase. Ac-CoA then enters the Kreb’s
cycle and an mcrease in the ATP/ADP ratio is produced. The increase in
ATP/ADP ratio inhibits the ATP-sensitive potassium channel which resuits in
depolarization cf the plasma membrane and opening of voltage-dependent
calcium channels (VDCC). A major increase in cytosolic calcium ensues
Figure 6. Model iflustrating glucose indnced insulin release in the
pancreatic -ceH: Calcium and JCATP channel dependent pathway.
Glucose enters the ccli via the glucose transporter GLUT 2. It is metabolized
and convefted te pyruvate via glycolysis which is subsequently oxidized in
the Kreb’s cycle causing an increase in the ATP/ADP ratio. The increased
ATP/ADP ratio closes the K ATP-dependent channel (resulting in
depolarization of the membrane) which causes opening of the Ca2 voltage
dependent channel and entry of Ca2 into the ceil. Ca2 activates exocytosis
of vesicles containing insulin granules. [GK, Glucokinase; G6P, glucose 6-
phosphate; F6P, fructose 6-phosphate; FDP, fructose I ,6-bisphosphate;
PFK, phosphofructose-kinase; aGPDH, a-glycerol 3-phosphate
dehydrogenase; GAPDH, glyceraldehydes 3-phosphate dehydrogenase;
LDH, lactate dehydro-genase; PK, pynivate kinase; Pyr, pyruvate; PDH,
pyruvate dehydrogenase; aKGDH, a-ketoglutarate dehydrogenase; ŒGP, (Z
glycerol 3-phosphate; fAD, flavin adenine dinucleotidej (Prentki 1996).
which triggers exocytosis of insulin (Prentki 1996) (Figure 6).
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7.2.2 rATP Channel Independent Pathways oflnsulin Secretion
It is clear however, diat some additional components of glucose metabolism
are needed for die full effect of glucose to be manifested. Prentki and Corkey
Prentld, Corkey 1996) raised the intriguing possibility that one such
component involves an element of glucose-fatty acid cross talk, in other
words, that die malonyl-CoAICPT I axis recognized in liver and later in the
muscle and heart, may also be at work in die -cel1 in relation to insulin
secretion.
7.2.2.1 Anapkrotic /Malonyl-CoA/Lipid Signaling Patkway
Prentki ami Corkey (Corkey, Glennon et al. 1989; Prentki, Vischer et al. 1992;
Prentki, Corkey 1996) proposed a model of -cell nutrient sensing and insulin
secretion in which, in addition to the KArp dependent pathway, a parallel
anaplerotic/lipid signaling pathway exists in which malonyl-CoA acts as a
coupling factor. The cascade of events proposed in the model is as follows
(Figure 7). Glucose is metabolised to pyruvate via glycolysis. Pyruvate is then
metabolised by eiffier pyruvate dehydrogenase (PDH) or pyruvate carboxylase
(PC). PDH transforms pyruvate to Ac-CoA, while PC, on the other hand, is an
anaplerotic enzyme which channels pyruvate into mitochondnal oxaloacetate.
The latter anaplerotic mechanism resuits in efflux of citrate from the
mitochondria to the cytosol. Cytosolic citrate is converted to Ac-CoA and
oxaloacetate via the action of citrate lyase (CL). Cytosolic Ac-CoA is then
carboxylated by acetyt-CoA carboxylase (ACC) to form malonyl-CoA.
Malonyl-CoA can enter fatty acid syndiesis via the action of the enzyme fatty
acid synthase (FAS) which uses malonyl-CoA as a substrate. FAS, however,
is not highly expressed in the -cells (Brun, Roche et al. 1996) such that in
response to elevated glucose and anaplerosis, cytosolic malonyl-CoA level
rises. Malonyl-CoA is an inhibitor of CPT I, die enzyme which catalyzes die
rate limiting step for fatty acid entry into the mitochondria to undergo f3-
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oxidation (Figure 7). Thus, CPT I inhibition by matonyl-CoA resuits in an
increase in long chain acyl-CoA in the cytosol which potentiates insulin
secretion either directly or indirectly by the production of complex lipid
signaling molecules, activation of protein kinase C (PKC), or by protein
acylation (Corkey, Deeney et al. 2000). In this model, malonyl CoA is
believed to act as a regutatoiy molecule and long chain acyl-CoA and its
metabolites as effector molecules in insulin secretion.
Glucose FFA
Figure 7. The regulation of cytosolic LC-CoA kvels.
Cytosolic LC-CoA is denved from either circulating FfAs or
endogenous complex Iipids. The entry of LC-CoA into the
mitochondria, where it is oxidized to acetyl-CoA, is confrolled by
malonyl-CoA derwed from glucose or offier fuels, which regulates
CPT I. AcCoA, acetyl-CoA; CL, citrate Iyase; CS, citrate synthase;
G6P, glucose-6-phosphate; OAA, oxaloacetate; PC, pyruvate
carboxylase; PDH, pyruvate dehydrogenase; PL, phospholipids;
TG, triglyccride. Adaptedfrom Prentki M Corkey B 1996.
The evidence supporting the existence of an anaplerotic/malonyl-CoAllipid
signaling in the (E-cell is summarized as follows: PC is abundant in the islet,
yet the islet is neither a neoglucogemc nor a lipogenic tissue; citrate, an
allosteric activator of ACC, nses markedly in response to glucose stimulation
before secretion occurs (Corkey, Glennon et aI. 1989; Roche, farfari et al.
1998; farfari, Schuiz et aL 2000); only nuinents which cause an increase in
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citrate levels cause insutin secretion (Brun, Roche et al. 1996); ACC is
abundant in the —celt; glucose increases ACC gene expression in INS ceils,
and basat insulin secretïon correlates with the content of ACC protein (Brun,
Roche et al. 1993); malonyl-CoA tises rapidly in response to glucose and only
nutrients that elevate malonyl-CoA cause secretion (Corkey, Glennon et al.
1989; Liang and Matschinsky 1991; Pren&i, Vischer et al. 1992). fAS is vety
low in the islets of Langerhans (Brun, Roche et al. 1996); potentiation of
glucose-induced insulin secretion resuits aftec iiicubating the (3-cetis with fatty
acids for a short penod (Malaisse, Sener et al. 1979; Prenfld, Vischer et al.
1992). Insutin release is promoted after inhibiting CYT I by pharmacologicat
agents (Prentki, Viseher et al. 1992; Chen, Ogawa et al. 1994); the levets of
fatty acyl-CoA in response to different nufrients correlate with insulin
secretion (Prentki, Vischer et aI. 1992). The above fmdings together provide a
strong evidence for the concept diat an anaplerotic/malonyl-CoAIlipid
signaling pathway plays an instrumental role in P-cetI nutrient signaling.
The following figure iltustrates the two patbways of insulin secretion in the l
ceti (Pren&i, Joly et al. 2002).
figure 8. Model illustratrng
signa n uc on pa way ici ia’iin the pancreatic -œlL When t
transiently stimulated, die Ac
CoA/Ca2 and anaplerotic/lipid
..tAcCoAi.
signaling pathways synergize i Aœ(
to promote insutin secretion. )AcCoAc, cytosolic acetyl-CoA; t’cclAcCoAm, mitochondrial acetyl- I
CoA; DAG, diacylglycerot; LPA, FAS
lysophosphatidic acid; fr, t1F (TE
oxidation of fatty acids; PA, s FaCŒAI
phosphatidic acid; PC, pyruvate ‘s QA
carboxylase; PDII, pyruvate s
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73 RaIe of FFA in Insulin Secretion
it is well documented diat acute FFA administration Ieads to augmentation of
glucose-stimulated msulm secretion (GSIS). ffA enhance both basal and
GSIS and are essentiat for stimulus-secretion couplmg in die pancreatic P-cett
(Boden, Chen et al. 199$; Dobbins, Chester et al. 199$). Efforts to elucidate
how fatty acids influence f-cell fimction led to a series of important fmdings
which implicate an element of g1ucose-fitty acid cross-talk in stimulus
secretion coupling within die -ceI1. 0f these fmdings that are of importance
and relevance to this thesis are: 1- exposure of Synan-hamster insulinoma
(HIT) celis or rat islets to glucose increases the cellutar malonyl-CoA content
which is proportional to die stimulation of insulin release (Codcey, Glennon et
al. 19$9; Liang and Matschinsky 1991; Prentki, Vischer et al. 1992); 2-
glucose concentrations whicb stimulate insulin secretion also suppress die
oxidation of long chain fatty acids (Tamarit-Rodriguez, Vara et aI. 1984); 3-
inhibitors of CPT I (like 2-bromopahuitate (2-BrP), 2- bromostearate (2-BrS)
and etomoxir) which reduce fatty acid oxidation (McGarry, Wockje et al.
1989; McGarry and Bmwn 1997) were found to stimulate insulin release from
pcrifused islets (Bliss and Sharp 1992), perfiised rat pancreas and in HIT ceils
(Prentki, Vïscher et al. 1992); 4- exogenous long chain fatty acids appreciably
potentiate GSIS from rat islets (Vara, femandez-Martin et al. 198$) and HIT
ceils (Pren&i, Vischer et al. 1992) which is concomitant with die nse in LC
CoA esters.
Ail offfiese fmdings are consistent wiffi die malonyl-CoAILC-CoA bypoffiesis
of Prendd and Corkey (Prendd and Corkey 1996). The increase in malonyl
CoA concentrations under these conditions suppresses CFT I activity and
therefore fatty acid oxidation. Tbis resuhs in an increase in die concentration
of cytosolic LC-CoAs which act as signating molecuies for insuiin secretion
in concert wiffi die risc in [C?], caused by die calcium and KArp channel
dependent paffiway. Glucose inhibition of LC-CoA oxidafion will be
associated wiffi much greater increase in LC-CoA levels where die exogenous
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FFA supply is simukaneously elevated, therefore amplifying die effect of
elevated FFA.
This rote of FFA in insulin secretion raises die question as to wheffier ail FFA
are equal in terms of their insulinotropic effects. To answer this question,
studies were carned out in the perfused pancreas and it was found that the
insulinotropic potency increased dramaticatly with increasing carbon chain
and wiffi a decrease in die number of double bonds (McGany and Dobbins
1999). The reason for this difference between saturated and unsaturated fatty
acids is flot clear. Wheffier dis is related to a difference in metabotism of the
two types orto a difference in de physicochemical properties of the effector
molecules still awaits an answer.
8. PATHOGENESIS 0F TYPE 2 DIÂBETES
Type 2 diabetes is a heterogeneous condition, die etiology of which is
polygernc and life style dependent (Kahn 1994; Zimmet, Alberti et al. 2001).
It is invariably charactenzed by progressive deterioration in insulin secretory
fimction, diminished hepatic glucoregulation and penpheral insuhn resistance
(Defronzo I 9$8; Porte 1991; Kahn 1994; Poitout and Robertson 1996;
Prendd and Corkey 1996; Prentki, Joly et al. 2002; Kahn 2003). Most often it
is associated with, and usually preceeded by central obesity and dyslipdemia
(Carey, Jenkms et aI. 1996; Wei, Gaskill et aL. 1997; Kahn 2003). The
majority of obese subjects, however, despite varying degrees of insulin
resistance, do not develop diabetes (Polonsky, Sturis et al. 1996; Mokdad,
ford et al. 2003). Insulin resistance, wheder due to obesity or physiological
conditions such as in pregnancy (Freinkel 1980; Catalano, Tyzbir et al. 1991),
is usually compensated by islet 8-ceils adaptation wiffi boffi increased 8-ceil
number and/or volume (8-ceil mass) and augmented B-ecu function (Kioppel,
Lohr et aI. 1985; Sorenson and Brelje 1997; Lingobr, Buettner et al. 2002;
Liu, Jetton et al. 2002; Butler, Janson et al. 2003; Kahn 2003). It is only when
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insulin resistance is accompanied by failure of the islet B-cell to compensate,
that type 2 diabetes (Kahn 2003) and gestational diabetes (Buchanan 2001)
develop. While the pathogenesis ofthe 6-celi failure is flot welI understood, it
is becoming increasingly evident from animal models (Coleman and Hummel
1973; Pick, Clark et al. 199$) and human autopsy senes (Stefan, Orci et al.
1982; Kioppel, Lohr et al. 1985; Clark, Wells et al. 19$$; Butier, Janson et al.
2003) that, in addition to B-cell dysflmction, reduction in B-cell mass is
involved.
The following figure illustrates the pathogenesis ami the course of type 2
diabetes. (adapted from Kahn 2000).
InitiatioH Factors Proeression Factors
- Insulin resistance genes - Obesity
- lasulin secretion genes - Toxrns affecting P-celk
- Obesity genes - Diet/Environmental
- Activity/Age
Type II Diabetes
Normal * Glucose tokraace
F:
I L..._..... L Dnsi apoptosisL l Insuim secretion (-ceII compensation phase)U Seasitivity to insulin (Insulin resistance)
Figure 9. Pathogenesis of type 2 diabetes.
Many factors contribute to the etiology of type 2 diabetes including
genetic and environmental factors. The genetic factors are likely to be
multiple involving genes that affect insulin secretion, msuhn
sensitivity and obesity. A decrease in the sensitivity to insulin by the
insulin target tissues resuits initially in augmentation of insulin
secretion by the f3-cells. This period is referred to as “f3-celI
compensation phase”. With time, there is a graduai Ioss 0f f3-ceIl
compensation resulting in a decrease in glucose tolerance. Factors such
as obesity, toxins and diet play a role in the progression ofthe disease
and in desensitizing the -cells to glucose. Eventually, there is a failure
of glucose induced insulin secretion, f3-cell death and thus the onset of
the established disease of type 2 diabetes.
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$1 Peripheral Insuhn Resistance
Type 2 diabetes is mvariably characterized by peripheral msutm resistance
which ptays a major rote in its development. Insulm resistance is defined as
the impaired ability of msutm to promote penpheral glucose disposai. Insulin
resistance is a hallmark of type 2 diabetes. Over 80 % of people with type 2
diabetes are obese, while virtually ail are insuim resistant (Boden 1997). Thus,
it is hypodiesized that there is a tight coffelation between obesity and rnsuim
resistance. Human and animal studies support this notion mdicating that
weight loss/gain correlates closety with increasing/decreasing msulm
sensitivity, respectively. Evidence indicates that rnsulm resistance is present
years beftwe die onset of die disease and it is considered as die best predictor
for die disease (ShuIman 2000). The penpheraI action of insuim primarily
includes die promotion of glucose uptake into skeletal muscle and inhibition
of lipotysis in adipose tissue which are both impaired with insuim resistance.
It bas also been shown that muscie glycogen synthesis is decreased by 60 % in
subjects with type 2 diabetes. Recent evidence have also mdicated diat insuim
resistance is also present in die -ceii which might contribute to die
abnormalities in insulin secreflon observed in type 2 diabetes (Withers,
Gutierrez et aI. 1998; Kuikami, Bmning et al. 1999). Many investigators have
studied die mecharnsms involved in insulin resistance at die level of die
insuhu receptor, die insulin-receptor signal transduction padiways, die insulin
regulated intermediaiy metabolic paffiways such as glycogen synthesis and
lipolysis and die transiocation of die insuhn sensitive glucose transporter
GLUT 4. Their fmdings are beyond die scope of this thesis other dian to say
diat elevated FFA bas been implicated in causing peripheral insulin resistance
and dis wilt be fiirther discussed below.
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8.2 Elevated Endogenous Glucose Production
Studies cf hepatic glucose metabolism in type 2 diabetes mvariably show
increasing basal glucose production and a failure of rnsulm to suppress
glucose production (Defronzo 198$; Kahn 1994). Elevated glucose
production is clearly important in die maintenance cf hyperglycemia in boffi
the basal (fasted) state and the post-prandial state.
83 Impaired Insulin Secretion
Impaired insulin secretion in type 2 diabetes is due to defects in fI-ceil
fimctiou and fi-celi mass. As discussed above, impaired insulin secretion is an
essential component in die padiogenesis cf type 2 diabetes.
8.3.1 Dysfunction
Islet dysfunction, characterized by loss of boffi first and second phase cf
glucose-induced insulin release, ptays an important role in die pathogenesis cf
hyperglycemia (van Haeften 2002). Defects in die first phase insulin secretion
are evident very early in die pathogenesis process with some studies showing
dis in subjects at risk of diabetes and diose wiffi impaired glucose tolerance.
Defects in second phase secretion occur later and continue to detenorate once
type 2 diabetes lias developed. Dysfimction is evident pafticularly with respect
to die ability of glucose to induce insulin secretion, as secretion to arginine is
preserved at least early in die pathogenesis process. There is considerable
evidence indicating a desensitization of die islet function during persistent
hyperglycemia in vitro (Grodsky 1989) and in vivo (Leahy, Cooper et al.
1986; Rossetti, Shulman et al. 1987; Leahy, Bonner-Weir et al. 198$).
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8.3.2 Loss offi-Cet! Mass
Another factor which plays an important role in failure of insulin secretion in
the etiology of type 2 diabetes is the reduction in the number of -cells.
Regulation of -ceI1 mass appears to mvoive a balance between -ceIl
replication and apoptosis and islet neogenesis from exocrine pancreatic ducts
(Finegood, Scagila et al. 1995; Bonner-Weir 2000). Disruption of these
processes causing either reduced -celI formation and/or increased rates of f
ccli death could cause a decrease in -cel1 mass and, as a consequence,
reduced msulin secretory capacity. There is controvcrsy wheffier -cell mass
is decreased in type 2 diabetes (Stefan, Orci et al. 1982; Kloppet, Lobr et al.
1985; Clark, Welis et al. 198$; Guiot, Sempoux et al. 2001) and this is due to
the scarcity of suitable pancreas specimens for histochemical analysis from
individuals wiffi type 2 diabetes. However, recent reports in which clinical
information was better characterized concluded that -ceIl mass ïs decreased
in type 2 diabetes (Kioppel, Lohr et al. 1985; Clark, Wells et al. 198$;
Sakuraba, Mizukami et al. 2002; Butler, Janson et al. 2003). Importantiy, in a
recently reported autopsy series (Butier, Janson et al. 2003), with adequate
subject number and pre-death clinical data, islet 8-ceil mass was shown to be
reduced in both impaired glucose tolerance and type 2 diabetic subjects and
was associated with evidence cf increased apoptosis. Thus, both type I and 2
diabetes are increasingly viewed as 8-celi mass defects.
8.4 Role of Elevated FfA in the Pathogenesis of Type 2 Diabetes
Evidence is mounting to support a “lipocentric” approach to the understanding
cf the metabolic derangements of type 2 diabetes rather than the traditional
“glucocentric” one (McGarry 1992). In support cf this approach, it has long
been known that, in addition te hyperglycemia, type 2 diabetic subjects aimost
invariably marnfest a serious breakdown in Iipid dynamics, reflected by
elevated levels cf circulating free fatty acids and triglycendes (1G) and
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reduced tevels of HDL cholesterot. Elevated plasma FFA are common in type
2 diabetes (Reaven, Hollenbeck et al. 19$8) and in some studies have been
shown to be predictive for the transition of patients from impaired glucose
toterance (IGT) to type 2 diabetes (Paolisso, Tataranni et al. 1995; Charles,
Eschwege et al. 1997). High plasma ffA concentrations are also associated
wiffi a number of cardiovascutar nsk factors Iinked to msulm resistance
including hypertension, dyslipidemia ami abnonnal fibrinolysis (Reaven
19$$).
Moreover, evidence from in vitro studies mvolvmg long-term exposure of rat
islets to high concentrations of fatty acids showed a paftem consistent with the
characteristic features of -ceIt dysfimction in human type 2 diabetes (Sako
and Gntl 1990; Unger 1995; McGarry ami Dobbms 1999). These wiIl be
discussed later under the lipotoxicity section. In addition, observations drawn
from expenments doue on obese type 2 diabetics ami on die Zucker diabetic
fatty rat (ZDF) raised die possibility diat in individuals genetically
predisposed to develop type 2 diabetes, long exposwe of die islets to elevated
concentrations of circulating FFA and VLDL or both might have a deleterious
effect on die -ceIl as welt as on die muscle and thus contribute to -cell
dysfunction. k is not clear, however, whedier dis breakdown in lipid
homeostasis is a resuh of die disease or is instrumental in its development.
8.4.1 Insulin Resistance and Etevated ffA
Studies have indicated diat elevated circulating ffA may conbibute to die
underlying pathophysiology of type 2 diabetes, in particular, die development
ofinsulin resistance boffi in die peripheiy and die liver (Boden 1997; Shulman
2000). Central obesity is strongly linked to elevated FFA levels wiffi central
adipocytes possibly being first affected by insulin resistance as proposed by
Bergman. (Bergman ami Mittehnan 199$). Widi die development of adipose
tissue insulin resistance, insulin-mediated suppression of lipolysis is decreased
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thus leadmg to increased circulating FfA ami ultimately insutin resistance in
skeletal muscle and liver (Boden 1997; Shulman 2000).
As mentioned cartier, skeletal muscle is also a major contnbutor to rnsulin
resistance in type 2 diabetes. A strong correlation is observed between
increased plasma FfA, intramyocellular lipid accumulation and insulin
resistance (Krssalç fa& Petersen et al. 1999; Perseghin, Scifo et al. 1999;
Boden, Lebed et al. 2001). ffA contribute to insuim resistance by havmg an
inhibitoiy effect early on in glucose utilization in die muscle at the level of
glucose transport (Cime, Petersen et al. 1999; Dresner, Laurent et al. 1999).
8.4.2 Endogenou Glucose Production and Ekvated ffA
Endogenous glucose production, mainly contributed by die liver, is mcreased
in type 2 diabetes (Boden and Shulman 2002). Plasma glucose levels have
been closety corrclated wiffi die rate of hepatic glucose production. Littie is
known about die mechanism of increased endogenous glucose production,
however, a mie for elevated FFA bas been postulated. Fligh circulating FFA
antagonize die effects of insuim to suppress endogenous glucose production.
ffA are known to stimulate endogenous glucose production by promotmg
gluconeogenesis as shown by animal and human studies (healdiy voluntcers
and type 2 diabetic subjccts).
8.4.3 Insulin Secretion
The physiologicat nature of die giucose-fatty acid cross-talk in stimulus
secretion coupling wiffiin die fi-ceil mentioned earlier, however, has a darker
side. In order to maintam glucose homeostasis, die pancreatic fi-ceil constandy
senses circulating nutrients and integrates diese signaIs to secrete insulin
accordingly. Abnormally elevated nuffient levels, however, may cause
detrimental effects possibly via die same signaling pathways implicated in
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msutm secretion. There is ample evidence that proionged efevations of
glucose “glucotoxicity” or FfA “tipotoxicity” are toxic to (E-cells and cause
boffi -cell dysfimction and apoptosis. Prentki and Corkey (Prendd and
Codcey 1996), however, hypothesized diat elevated glucose would mcrease
the toxicity ofelevated fFA, a concept tenned “glucolipotoxicity”. Isiet î-cell
glucotoxicity, lipotoxicity and glucolipotoxicity wili be discussed in detail
below.
9. ISLET p-CEu FAILURE IN TYPE 2 DIABETES
9.1 Glncotoxicity
As mentioned earlier, the traditional approach to the understanding of type 2
diabetes pathogenesis was more “glucocentric”. This was based on a
considerable body of evidence suggesting that chronic hyperglycemia impairs
glucose-induced insuim secretion and msulin gene expression (LeRoith 2002;
Poitout and Robertson 2002). This is due to a diminished activity oftwo major
fI—ceil transcription factors, pancreatic-duodenum homeobox-1 (PDX-1)
(Oison, Redmon et al. 1993; OIson, Shanna et al. 1995) and die activator of
die rat insuim promoter element 3b1 (Sharma, Oison et al. 1995; Poitout,
Oison et al. 1996). The effects ofprolonged hyperglycemia on (l-cell fimction
mclude distinct phenomena: glucose desensitization, (E-cell exhaustion, and
glucotoxicity. Glucose desensitization is a physiological adaptive mecharnsm
and refers to die rapid and reversible refractonness of die -ce1l exocytotic
machinery following a short exposure to elevated glucose. -cell exhaustion,
however, refers to die depletion of die readily reteasable pool of intracellular
insulin following prolonged exposure to a secretagogue (Sako and Grill 1990;
Leahy, Bumbalo et al. 1994). The tenu glucotoxicity describes die slow and
pmgressively “irreversible” effects of chrornc hyperglycemia on pancreatic I1-
ceil fiinction. These defects of die -ce11 are reversible up to a certain point in
tùne after which ffiey are irreversible. This suggests that -ceII exhaustion and
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glucotoxicity is a continuum process, in which ffie latter becomes predominant
afler proÏonged exposure to glucose (Moran, Zhang et al. 1997; Gleason,
Gonzalez et al. 2000). In vitro and in vivo studies have shown that chronic
hyperglycemia can decrease -cell mass by inducing apoptosis (Efanova,
Zaitsev et al. 199$; Pick, Clark et al. 199$).
Generation of oxidative stress has been reported as a biochemical basis of
glucotoxicity (Matsuoka, Kajimoto et al. 1997; Tajiri, Moller et al. 1997;
Ihara, Toyokuni et al. 1999; Tanaka, Gleason et al. 1999). Evidence from
isolated islets chromcally exposed to elevated glucose levels in vitro Ied to
accumulation of advanced glycation end-products, (AGE), impaired P-ceIl
function, and apoptosis, ail of which can be prevented by antioxidant agents
(Kaneto, Fujii et al. 19%; Tajiri, Moller et al. 1997). Normalization of plasma
glucose levels and restoration of msulin secretion, insulin content, and insulin
mRNA levels were achieved in the ZDF rats with antioxidants (Tanaka,
Gleason et al. 1999). ibese fmdings support die hypoffiesis that glucotoxicity
is mediated, at Ieast in part, by chronic oxidative stress.
9.2 Lipotoxieity
A lipocentric approach is increasingly being taken in attempts to understand
die pathogenesis of type 2 diabetes. fatty acids (FA), which are essential
-
celi fuels in the normal state, are toxic when present at elevated levels for long
penods of time. This notion is supported by studies in isolated islets exposed
to high concentrations of FFA for periods of 2448h (Zhou and Grill 1995;
Boiffleimer, Skelly et al. 199$). This resulted in enhanced insulin secretion at
low glucose concentrations, depressed proinsulin biosynthesis, depletion of
insulin stores, and an impaired response of die -ce11 to stimulatory
concentrations of glucose, i.e., characteristics of type 2 diabetes. More
evidence supporting dus notion of “lipotoxicity” cornes from studies widi die
ZDf rat, a model which shares many of die featiwes of obcsily-related type 2
32
diabetes in humans. A striking feature of this animal model is a pronouuced
increase in plasma NEFA and triglyceride concentrations in the perdiabetic
phase and a sharp increase in islet triglycende content unmediately before the
hyperglycemia appears, which is usually at about 9-11 weeks of age (Bamett,
Collier et al. 1992; Eec, Hirose et al. 1994). Unger and colleagues (Barnett,
Collier et al. 1992; Eec, Hirose et al. 1994) found that diet restriction of these
animais greatiy reduced their hyperlipidemia including FFA levels and, in
association, islet function was largely restored and hyperglycemia did flot
develop. Under these conditions, there was no hyperglycemia and a
substantial improvement of -ce1l function was clearly evident, i.e. the entire
phenotype of type II diabetes was prevented. The sanie relationship between
increased TG content and deranged -ceI1 fiinction was seen dunng long tenn
exposure of rat islets to bigh fatty acid levels in vitro (Zhou, Ling et al. 1996).
Fwlher studies from Unger and colleagues in the ZDf rat (Wang, Pan et ai.
2001) focused on the mechanîsms underlying islet lipotoxicity. Fatty acid
mediated upregulation of inducible nitric oxide synthase (INOS) and ceramide
synthesis (Figure 10) were both shown to be confributing to f3-cell apoptosis, a
documented event in the ZDF rat. Collectively, this body of work implicates
fat accumulation in the islet as an important contributor to (3-celi demise in the
ZDf rat (and probably in other rodent models of obesity associated type 2
diabetes).
further support for the ‘lipotoxicity’ hypothesis cornes from experiments
investigating the effect of troglitazone in islets from ZDf rats (Shimabuktwo,
Zhou et al. 199$). Incubation of ZDF rat islets wiffi froglitazone resulted in
improvement in insulin secretion in association with a reduction in the
markedly increased islet triglyceride content as obsewed in untreated islets.
These data support the hypothesis that increased circulating FfA and istet
lipid accumulation are responsible for the suppression of insulin secretion
scen in ZDf rats. One possible mechanism for the proposed lipotoxicity is that
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surplus unoxidized FfA (characterized by elevated islet friglyceride content)
increases the formation of nitric oxide (NO), which induces -cell apoptosis
(Unger, Zhou et al. 1999) (Figure 10).
[11 Apoptosis
Prolonged exposure of pancreatic 3-cells to FFA mcreases basal msulm
release but inhibits glucose-mduced msulin secretion (McGany and Dobbins
1999). In addition, FfA inhibit msulin gene expression in the presence of
elevated glucose levels (Gremlich, Bonny et al. 1997; Ritz-Laser, Meda et al.
1999; Jacqueminet, Bnaud et al. 2000), in part via negative regulation of the
transcription factor PDX-i (Gremlich, Bonny et al. 1997). finally, excessive
ffA induces f-celI death by apoptosis both in vitro (Cnop, Hannaert et al.
2001; Maedler, Spinas et aI. 2001) and in ZDF rat islets (Pick, Clai* et al.
199$; Shimabukuro, Higa et al. 1998).
9.3 Glucolipotoxicity: Glucose and FFA Synergize in Mediating p-CelI
Toxicity
To reconcile and integrate the roles of elevated glucose and ffA in the
pathogenesis of type 2 diabetes, Prentki and colleagues proposed the
glucolipoxia concept (Prentki and Corkey 1996) which has subsequently been
termed glucolipotoxicity (Prentki, Segail et al. 199$). The biochemical basis
Figure 10: The proposed pathway
of lipoapoptosis in the islets of the
ZDF rat via the de novo pathway of
ceramide. (Unger, Zhou et al.
1999). The formation of ceramide is
catalyzed by the enzyme serine
palmitoyl transferase (SPT) which is
expressed at high levels in the ZDf
rat islets.
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of dis hypothesis is underpinned by the -ce1l anaplerosis/malonyl-CoAIlipid
signalmg model. This hypothesis states that the toxic actions of elevated FFA
on vanous tissues will become pafticularly apparent in the context of
hyperglycemia. Elevated glucose levels resuits in accumulation of cytosotic
citrate, die precursor of malonyl-CoA, which inhibits CPT I. This curtails fat
oxidation ami consequently cellular detoxification of fatty acids. Under
circumstances wbere both fFA and glucose are elevated, accumulation of
metabolites denved from fatty acid esterification would inhibit glucose—
induced insulin secretion ami insulin gene expression and would also cause fi
celi deaffi. Thus, glucose induces and activates enzymes and transcription
factors involved in fat synthesis and storage and simultaneously switches off
fat oxidation via die accumulation of malonyl-CoA (McGany ami Brown
1997; Roche, Farfan et al. 199$; Jacqueminet, Briaud et al. 2000) and
reduction hi die expression level of peroxisomal proliferator activated
receptor-ti (PPARŒ) (Roduit, Morm et al. 2000). Sustained inhibition of fat
oxidation resuits in an accumulation of long chain fatty acyl-CoAs (LC-CoA)
which are ffiought to mediate die effects of chronically elevated FfA (Pren&i
and Corkey 1996). Whether LC-CoA accumulation affects de 8-celi
(Kraegen, Cooney et aL 2001) directly or indirectly via triglycende deposition
or act as precursors for other lipid signating metabolites such as
phosphatidate, diacylglyceml and ceramide is unknown. 0f note, die
accumulation of LC-CoA in muscle, also via elevation of glucose and FFA
togeffier, has been implicated in die paffiogenesis of insulin resistance via
chronic activation of protein kinase C isofonus or ceramide (Ruderman, Saha
et ai. 1999; Kraegen, Cooney et ai. 2001). For early 8-celi failure to occur, die
hypoffiesis proposes dat high normal postprandial glucose excursions,
togeffier with hyperlipidemia and elevated postprandial FFA levels, act in
synergy to cause the initial B-cell failure (Prentki, JoIy et al. 2002) (Figure
11). The process is then likely to accelerate once hyperglycemia bas
developed.
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Evidence to support this hypoffiesis has accumulated from many labs. first, in
isolated islets differential effects of palmitate exposure on insulin gene
expression are seen in the presence of Iow vs. high glucose concentrations
(Jacqueminet, Bnaud et al. 2000). A 72-h culture in the presence of pahuitate
does not affect insulin content or insulin mRNA levels at low glucose but does
so at high glucose. Second, a prolonged culture of islets wiffi palmitate is
associated with glucose-dependent incorporation of FA into neutral lipids
(Briaud, Harmon et al. 2001). It was found that glucose and palmitate have
additive effects on FA metabolism into triglycendes (TG) only at elevated
glucose levels.
These resuhs clearly support the hypoffiesis that hyperglycemia is required for
lipotoxicity to occur. They are consistent with the clinical observation that the
majority of hyperlipidemic indwiduals have normal -cell fimction and
obesity and/or dysÏipidemia are not sufficient to cause -cel1 dysfunction.
figure 11: Possible mechamsm of (1-ceil glucolipotoxicity
implicating malonyl-CoA, PPAR-a and altered lipid partitioning. ACO,
acyl CoA oxidase; DAG, diacylglycerot; G3P, glycerol 3-phosphate; PL,
pbospholipids; UCP2, uncoupling protein 2.
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Ilius, accordmgly glucotoxicity and Iipotoxicity are closely interrelated in die
sense diat lipotoxicity does flot occur without chromc hyperglycemia and both
are required to converge toward die generation of damaging effectors on f3-
ceil function. Thus, lipotoxicity can be viewed as one mechanism of
gtucotoxicity.
9. AIMS 0F THE THESIS
The Role of Glucose and Fatty Acid Synergy in li-Celi Toxicity in flic
Pathogenesis of Type 2 Diabctes
To date die actions of glucose ami fatty acids on 8-ceil growth and death have
been studied mostty independently. As explained in die introduction above,
we hypoffiesized that die toxicity ofelevated FFA would be much enhanced in
die context ofhyperglycemia a concept which we termed “glucolipotoxicity”.
The main aim of dis desis, dierefore, was to investigate die rote of synergy
between elevated glucose and FFA on 8-ceil toxicity.
Specific Objectives
1. To determine die effects of elevated glucose atone and vanous FFA
(saturated, monouusaturated and polyunsaturated) at bodi low glucose and
high glucose on 8-celi deaffi.
2. To determine die mode of B-cell death (apoptosis vs necrosis) induced by
elevated glucose, elevated FFA or die combmation of elevated glucose and
FFA.
3. To determine, as proposed by die model of glucohpotoxicity, whether die
inhibition of fatty acid oxidation by elevated glucose is involved in die
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mechanism of synergy bctween elevated glucose and fFA in causing B-celI
death.
4. To determine whether the de novo pathway of ceramide synthesis is
involved in gtucolipotoxicity.
Perspectives:
The 8-ceil glucolipotoxicity concept, if successfiilly verified by the planned
studies, wiIl be of major importance to the fields of diabetes reasearch and
practice. It wilI be a major advance in the understanding of the pathogenesis
of type 2 diabetes which wilI guide the development of both preventive and
treatment strategies for this disease. This concept may also be of importance
in the understanding of the paffiogenesis of type I diabetes. Whereas the
major etiologic factor for this disease is undoubtedly immunologie,
glucotipotoxicity could be involved in markedly increasing the rate ofdecline
in B-celI mass once glucose levels start to rïse. Glucolipotoxicity may also be
involved in loss of the replaced 8-celi mass which occurs in the early phases
of islet transplantation in the keatment of type 1 diabetes. Thus, dietary and
pharmacologie strategies aimed at limiting glucolipotoxicity, thereby
enhancing fi-ceil survival, may be of importance in the management of ail
forms ofdiabetes.
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CHAPTER 2: Matenals and Methods
Materials. Regular and glucose-free RPMI medium and ccli culture
supplements were purchased from Invitrogen (Burlington, Ont, Canada). The
caspase-3 substrate Ac-DEVD-AFC, the pan-caspase inhibitor z-VAD-fiidç
die ceramide inhibitors fiimonisin Bi (F81) and myriocin and die acyi-CoA
synthase inhibitor triacsin C were purchased from Biomol (Plymouth Meeting,
PA). Fatty acids were purchased from Nu-Check Prep (Elysian, MN). fatty
acid-free bovine semm albumin (BSA) (fraction V), etomoxir, MCAR,
mefformin, Hoechst 33342 (bis-benzimide) and propidium iodide (PI) were
obtained from Sigma (St Louis, MO). n-Octyl-B--D-giucopyranoside and
diacylglyceroi kinase were purchased from Calbiochem (San Diego, CA), ami
dioleoyl-phosphatidyl-glycerol from Avanti Polar Lipids (Alabaster, AL). [y
32PJATP was from Amersham Pharmacia Biotech (QC, Canada). Siica Gel 60
thin-layer chromatography plates were from Whattuan (New Jersey, USA).
Ccli Culture. INS $32/13 celis (kindly provided by Dr. C.B. Newgard, Duke
Unîversity) (Hohmeier, Mulder et al. 2000) between passages 36-70 were
grown as previously described (Mfari, Janjic et al. 1992) in monolayer at
37°C widi 5 % CO in regular RPMI-1640 medium at li mM glucose
supplemented wiffi 10 % heat-inactivated fetal bovine serum (FBS), 10 mM
HEPES (pH 7.4), 2 mM L-glutamine, 1 mM sodium pyruvate and 50 iM B
mercaptoethanot (complete medium). To measure glucose and FFA induced
ccli death, ceils were seeded at a density of 4x104 ceils/cm2 and grown for two
days in complete RPMI. After die culture establishment period, medium was
removed and oeils were dien incubated in RPMI medium supplemented as
above with 1 % FBS (descnbed thereafier as RPMI incubation medium), at
either 5, 11 or 20 mM glucose in die presence of 0.5 % BSA aJonc (control) or
wiffi various FFA (0.25, 0.3 or 0.4 mM) bound to 0.5 % BSA as indicated. In
some expenments, following culture establishment, ceils were pre-treated
wiffi die inhibitors, zVAD-fink (50 pM), fB1 (50 jiM), myriocin (20 iiM),
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etomoxir (0.2 mM), friacscin C (5 1iM) for 1-2 h as mdicated in complete
RPMI containmg 10 % fBS, followed by FfA treatment at 5 or 20 mM
glucose in complete RPMI contaming 1 % FBS (incubation medium) for 24 h,
also, in die presence of the inhibitor. The antidiabetic agent metfonnin (0.5
mM) ami the AMPK activator AICAR (1 mM) were added togeffier with die
FfA for 24 h in complete RPMI containing 1 % fBS.
Prepartion of BSA-Bouad fatty Acids. Stock solutions of fatty acids
bound to BSA were prepared as descnbed by Roche and cou. (Roche, Buteau
et al. 1999). Bnefly, a saturatmg quantïty of the sodium sait fauy acid was
dissolved at 37°C for 16 h under a nhirogen atmosphere in Krcbs-Ringer
bicarbonate buffer containmg 10 mM Hepes (pH 7.4) buffer (KRBH) amI 5 %
(wtlvol) fatty acid-free BSA. Solutions were then filtered through a 0.2 tm
filter. BSA-bound FFA was quantitated using die NEFA C kit (WAKO
chemicals GmbH, Gennany) ami stock solutions were fmally adjusted to 4
mM FfA using 5 % fatty acid frec BSA in KRBH and stored at -20°C.
Qnantification of Ccli Death. INS $32113 celi viabilïty was detennined by
the abitity of cetis to exciude tiypan bine. b discriminate between necrosis
ami apoptosis, cetls were double stamed with die fluorescent DNA-staining
dyes Hoechst 33342 and propidïum iodide (PI). INS $32/13 cdils (8x1 ceils)
were seeded on 12 mm glass coverslips placed in 24-weIl plate in comptete
RPMI medium for two days. Medium was changed to suppiemented RPMI
containing I % FBS, 0.5 % BSA, at either 5, Il or 20 mM glucose wiffi or
without the varions FFA (0.25, 0.3, 0.4 mM) as indicated for an additional 24
h. At die end of die treatment period, oeils were stamed with Hoechst 33342
(10 jtg/mI) ami PI (1 rgIm1) in media simultaneousiy for 30 min at 37°C.
Coverslips were then placed on slides and the stained nuclei were immediately
visualized by fluorescence microscopy widi a Zeiss Axioskop microscope
usmg Hoechst and PI filter sets. Celis were defined as apoptotic when they
exhibited a condensed nuclear chromatin or a fragmented nuclear membrane
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when visuahzed widi Hoechst 33342. Necrotic ceils were characterized by
nuclear PI staming but without condensed chromatm or fragmented nuclear
membranes. CeIls widiout apoptotic or necrotic features were considered
viable. Quantitative anatysis of each sample was perfonned by randomly
choosmg 5 fields and by counting at least 200 cells per assay condition.
Annexrn staining: Annexin-V is a phospholipid-bmdmg protem with a high
affmity for phosphatidylsenne (PS). Detection ofcell-surface PS wiffi annexin
V serves as a marker for apoptotic celis. Annexin V will flot bmd intact
normal ceils. It will detect apoptotic ceils widi membrane alterations (PS
transtocation). To differentiate apoptosis from necrosis, celis are
simultaneously stamed wiffi Annexin V and PI. 1NS 832/13 cells were grown
on coverslips as mentioned earlier for ccli deaffi quantification. After die
treatment period, coverslips were rrnsed wiffi iX binding buffer and dien
stained wiffi Annexin-V fITC and PI according to die manufacturer’s protocol
(Clonetech) for 15 minutes at 37°C at room temperature in die dark.
Coverslips were dien washed, placed on slides ami visualized under
fluorescent microscope using a dual filter set for HTC and rhodamine. CeiLs
having an intense green fluorescence surrounding die plasma membrane are
considered apoptotic ceils. Ceits with green staining and red cytoplasm
staining are considered late apoptotic ceils which have Iost dieir membrane
integrity.
Western Bloffing: for experiments analyzing poly (ADP-nbose) polymerase
(PARP) cleavage, ceils were seeded and b-eated as indicated earlier. At 24 h
foliowing freatment, oeils were scraped and washed wiffi ice-cold PBS,
centrifuged at 1000 rpm for 10 minutes at 4°C. The ccli pellet was then
resuspended in a reducing loading buffer according to die manufacturer’s
instructions (Enzyme Systems Products, Livermore, CA) (62.5 mM Tris, pH
6.8; 6 M urea 10 % glycerol; 2 % SDS; 0.003 % bromophenol blue; 5 %
-
mercaptoethanol), and sonicated for 20 sec on ice. Protein concentrations were
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determined using the Pierce assay. Equat amounts of protem, 50 tg, were
mcubated for 15 mm at 65°C before loadmg on SDS-PAGE (8 %) and then
transferred to nitrocellulose membrane. Boffi the native (116 Kd) and the
cleaved ($6 Kd) bands of PARP were i&ntified by the polyclonat antibody
(419) (Enzyme Systems Products) used at a dilution of 1:15000 and an anti
rabbit conjugated to peroxidase (Jackson laboratories) secondary antibody at a
dilution of 1:10000. The signal was visualized by enhanced
chemiluminescence (Amersham-Pharmacia biotech).
In vitro Caspase-3 Activity Assay. Caspase-3 actwity was mcasured usmg
the substrate Ac-DEVD-AFC and was assayed according to the
manufacturer’s protocol. Bnefly, 1NS $32/13 celis established in cutture were
incubatedfor24hinRPMlcontainingl%FBSandO.5%BSAat5or2O
mM glucose wiffi or wiffiout vanous fatty acids (0.25, 0.3, 0.4 mM) as
mdicated in figure lcgends. Both adherent and unattached ceils were then
harvested ami combined. After sedimentation at 500 g for 10 mm, the celis
were washed twice with ive cold PBS, lysed for 10 min on ice with a ccli lysis
buffer (Invitrogen), and centrifliged (10 mm, 15,000 g, 4°C) to remove debns.
fifty micrograms ofproteins detennined by die BCA protein quantification kit
(Pierce) were incubated for 30 min with 50 iM Ac-DEVD-AFC at 30°C.
Fluorescence was analyzed using a FluoStar-Optima micmpfate reader (BMG
Iab Technologies, Offenburg, Gennany) in fluorescence mode using an
excitation filter of 380 nm (10 mn bandpass) and an emission filter of 505 mn
(bandpass 10 nm). The reaction was allowed to proceed for 30 min with a
reading every minute. Caspase-3 activities were obtained by calculating die
siope of the reaction over 30 min and by reporting die siope for each
condition.
Centmide Measuremeni INS $32/13 ceils were seeded in complete RPMI
medium at 11 mM glucose containing 10 % fBS in 6-well plates and grown
for 2 days. They were then incubated for 24 h in supplemented RPMI
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containing I % FBS at 5 or 20 mM glucose with or wiffiout the varlous faily
acids bound to 0.5 % BSA. Lipids were extracted according to the method of
Bligh and Dyer (Bligh ami [)yer 1959). Bnefly, ceils were scraped, washed
wiffi PBS and the Iipids were extracted with 3 ml chloroform/methanol (12,
v/v) in 13 X 100 mm screw-top glass tubes. The monophase was
supplemented with 0.7 ml distffled water, and after vigorous mixing the
phases were left to settie for 10 min. following the fiirther addition of 1 ml
chloroform and 1 ml water, shaking and centrifugation at 500 g for 5 min at
room temperature, the organic and aqueous phases were separated. The
organic phase was transferred tu new tubes ami dried under nitrogen. Lipids
were then resuspended in 1 ml chlorofonu and stored at -80°C. Ceramide
levels were measured using a modified Eschenchia cou diacylglycerol kinase
assay (Preiss, Loomis et al. 1986; Okazaki, Bielawska et al. 1990) using
external standards. Sixty percent ofeach ofthe lipid samples was drted under
N2 ami then solubilized by sonication in a bath sonicator in 20 tl octyl-f3-D-
glucoside (7.5 %dioleoy1-phosphatidy1glycerol (25 mM) micellar solution.
The reaction buffer was prepared using a 2x solution [containing 10 mM
imidazolefHCl buffer (pH 6.6), 100 mM LiCI, 25 mM MgC12 and 2 mM
EGTA], mixed wiffi an equat volume of dilution buffer [10 mM imidazote/1
mM diethylenetriamine-penta-acetic acid (pH 7.0)]. Ninety jil 0f reaction
buffer was added to the tipid micelles togeffier wiffi 5 ig of diacylglycerol
kinase. The reaction was started by adding 10 .d of 2.5 mM y32P-ATP solution
(specific activity of 6,000 Cilmmol) and allowed tu proceed for 30 min at
room temperature. Lipids were re-extracted as described above and the
orgamc phase was dried under nifrogen. Lipids were then resuspended in 50
pI methanollchloroform (1:10, vlv), and 25 tI were spotted on silica gel TLC
plates along with ceramide standards (Sigma). Plates were then mn wiffi
chloroformlacetone/methanoUacetic acidlwater (50:20:15:10:5, by vol) mobile
phase, and subjected to autoradiography. The radioactive spots corresponding
tu ceramide phosphate were scraped and counted on a scintillation counter.
Linear curves of ceramide pbosphoiylation were produced wiffi externat
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standards. Ceramide levels were normalized to total lipid phosphate. Briefly,
40 % of the lipid sample was dried down under nitrogen and oxidized wiffi
0.15 ml of 70 % perchioric acid at 160°C for 45 min. The tubes were allowed
to cool before adding 0.83 ml water, followed by 0.17 ml of 2.5 % ammonium
molybdate and 0.17 ml cf 10 % ascorbic acid. The tubes were then incubated
at 50°C for 15 mm, and the absorbance was read at $20 nm and compared
with standards.
Statistical analysis. Data were analyzed by ANOVA followed by Bonferroni
post-hoc test. P<O.05 was considered significant. Data are expressed as mean
± standard error cf the mean (S.E.).
44
CHÂFEER 3: RESULTS
1. Optimization of Culture Conditions for B-Cell Toxicity Experiments.
Culture conditions for INS $32/13 celis were established considering several
factors; firstly, we wanted to work in conditions that mimic islets in vivo in
the sense that diere is minimal proliferation. Secondly, INS $32/13 celis
proliferate rapidly when cultured at high compared to low glucose
concentrations in 10 % FBS. For these reasons, in order to select the lowest %
ofFBS at which both ceil death and proliferation is minimal, INS $32/13 cdils
were cukured in complete RPMI medium at Il mM glucose with 10, 5, 2, 1,
0.5, 0.2 and O % FBS for 96 hours and ceil viability was assessed by the
ability of celis tu exciude trypan blue. At 96 h in 1 % FBS, die percent ceil
death was around 15 percent in comparison tu die five percent with 10 % FBS
(Figure 12). Thus, I % FBS concentration was chosen to mn ail assays.
5 2 1 930 0
Ser (¾)
Figure 12: Optimuation of culture conditions. INS $32/13 celis
were cultured in complete RPMI media at 11 mM glucose in 24-wdll
plate at a density of 0.0$x106 cells/wetl. The medium was then
changed containing different percentages of semm as indicated for
anoffier 96 hours. At die end of die incubation period, ceils were
harvested by trypsinization and both ceil death and celi density were
calculated using die trypan blue exclusion meffiod.
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2. Varions Fatty Acids have Differential Effects ou fi-cet! Death whwh, for
Some are Highly Glucose Dependent.
INS 832/13 cells were treated for 24 h with different concentrations of FfA
(J)almitate, oleate and linoleate) at 5 and 20 mM glucose. At 5 mM glucose,
palmitate and linoleate, even at high physiological concentrations (0.4 mM),
showed minimal toxicity (Figure 13 A, C).
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Figure 13. Dose response curve of FFA.
After establishing the celis in culture, the INS $32/13 celis were
cukured for 24 h in RPMI incubation medium containing 0.5 % BSA
at 5 (G5) and 20 (G20) mM glucose in the absence (control) or
presence of 0.05, 0.1, 0.2, 0.3, 0.4 mM FFAs. After treatment, both
adherent and floating ceils were collected, combined and the ceils
were stained with trypan blue. Positive (dead) and negative (live) ceils
were counted. Resuits are expressed as percent of total celi number. #,
P0.01 compared to palmitate 5 mM glucose. t, P<0.05 compared to
linoleate at 5 mM glucose. ##, P<0.01 compared to palmitate at 5 mM
glucose ami linoleate at 5 mM glucose.
#
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At this low concentration of glucose, oleate at 0.3 and 0.4 mM was
moderateiy toxic which has been recently observed by another group (Figure
13B) (Wrede, Dickson et al. 2002). At 20 mM glucose, however, palinitate
and linoleate caused celi deaffi at concentrations greater than 0.2 mM (Figure
13A,C). In contrast, at 20 mM glucose, oleate was flot toxic at ils highest
concentration (0.4 mM) (Figure 13B). Thus 0.3 or 0.4 mM of palmitate and
0.4 mM of linoleate and oleate were used to mn subsequent expenments with
ail FFAs used except for stearate which was used at 0.25 mM because of its
high toxicity at eievated glucose levels smce toxicity of FFA increases with
cham length.
1NS 832/13 ceils were then exposed for 24 h to 5, 11 or 20 mM glucose in the
absence or presence of the three most abundant FFA found in the blood i.e.
saturated palmitate (C 16:0), monounsaturated oleate (C 18:1) and
polyunsaturated linoleate (C 18:2) (Figure 14). In the absence of exogenous
FFA, celis exposed to 5 and 11 mM glucose showed minimal ccli death (less
than 5 %) as measured by trypan blue exclusion. Elevated glucose (20 mM)
caused a modest increase in ceil deaffi that reached 7 % of total celi number.
At 5 mM glucose, ail tested FFA increased ccli death 1 .$-2.0-foid. Higher
glucose concentrations markedly increased the lipotoxicity of palmitate, had
an intermediate effect on the lipotoxicity of linoleate, but had no effect on the
toxicity ofoleate. Thus, a dramatic synergistic action ofpalmitate and glucose
on ceil deaffi was observed at both 11 and 20 mM glucose (Figure 14).
Linoleate did synergize with elevated glucose but in a reduced manner. In
marked contrast, oleate showed low cytotoxicity at the eievated glucose
concentrations examined. Vanous fatty acids, therefore, are not equivalent
with respect to their action on ccii death and the cytotoxicity of some fatty
acids is markedly glucose dependent.
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Figure 14: Effect of varlous frce fatty acids at different glucose
concentrations on fi-celi death. INS 832/13 cells were cultured for 24 h
in RPM1 incubation medium as described in methods containing 0.5 %
BSA at 5 (G5), Il (G!!) or 20 (G20) mM glucose in the absence (control)
or presence of 0.4 mM palmitate (Pal), oleate (01) or linoleate (Lin). Afler
treatment, both adherent and floating celis were collected and combined
and the celis were stained with trypan blue. Positive (dead) and negative
(live) celis were counted. Resuits are expressed as percent of total ccli
number. Data are mean ± S.E. of three different expenments. One-way
ANOVA with Bonferroni post-hoc test; , P<0.001 compared to control at
same glucose concentration. ** P<0.001 compared to corresponding
paimitate at 5 and 11 mM glucose.
The cytotoxicity induced by high glucose alone however was further increased
at 4$ and 96 h to 18.5±1.31 and 36.3±8.5 %, respectively (Figure 15).
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Figure 15: lime dependence of
the apoptotic action of elevated G5
glucose on the -cell. 1NS ‘35 “>G2o
$32/13 celis were cultured as in
figure 14 in the presence of 25
glucoses and 20 mM for 24,48 20
and 96 h as indicated in the
..
figure. P<O.05 for 20 mM 15
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3. Saturated Fatty Acids are Particularlv Efficient in Synergizing with
Glucose to Induce l-CelI Apoptosis.
To determine the mode of ccli death induced by the various FFA at elevated
glucose. INS 832/13 ceïls were stained with the dye Hoechst 33342 (Figure
16). Eievated levels of glucose (2(] mM) caused minimal apoptosis at 48
hours. Saturated fafty acids (paimitate and stearate) and the polyunsaturated
FfA linoleate also caused considerable apoptosis as indicated by DNA
condensation at 20 mM glucose (Figure 16 show’n by the arrows). Oleate vas
iiot toxic at 20 mM glucose as the amount of apoptosis with oleate vas
equivaient to that of 20 mM glucose without fatty acid. Examples ofapoptotic
nuclci are shown in Figure 1 6. and the quantification of condensed nuclei at 5
and 20 mM glucose at 24 h is shown in Figure 17.
To examine whether ccli death induced by various FFA at elevated glucose
occurs via necrosis as well as apoptosis. INS 832/13 cells were stained with
Palmitate/G20
Stearate/G20 Oleate/G20 Linoleate/G20
figure 16: High glucose and different FfA caused W%A
condensation to various extents. 1NS $32/13 cells were seeded on
glass coverslips and then treated at 5 or 20 mM glucose in the absence
(control) or presence of (0.4 mM) palmitate. oleate. linoleate or (0.25
mM) stearate for 42 h. CeNs were stained with Hoechst 33342 and
then visualized using fluorescence microscopy. Examples of
condensed nuclei. a hallmark of apoptosis. are indicated hy arrows
49
the dyes Hoechst 33342 and PI to distmguish both types of ceil death (figure
17). Under ail tested expenmental conditions (various fatty acids at different
glucose concentrations) the percentage of necrotic celis was modest (less than
7 %), except for palmitate at 20 mM glucose (1$ %) (figure 17).
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Figure 17: Quantification of the effect of vanous free fatty acids at
different glucose concentrations on li-celi apoptosis and necrosis. INS
832/13 cells were cultured for 24 h as described in Figure I at 5 (G5), 11
(G Il) or 20 mM (G20) glucose in ffie absence (control) or presence of 0.4
mM palmitate (Pal), oleate (01), linoleate (Lin) or (0.25 mM) stearate (St).
Celis were then stained with the dyes Hoechst 33342 and PI, analyzed by
fluorescence microscopy and scored according to the morphology ami
type of the fluorescence of the nucleus, as described in the methods
section. Resuits are expressed as percent of total ceit number for A.
Apoptotic celis and B. Necrotic ceils. Data represents means ± S.E. of four
different experiments. , P<0.001 compared to control at same glucose
concentration. P<0.05 and P<0.00I compared to control at 5 mM
glucose. #, P<0.05 compared to stearate at 5 mM glucose. #, P<0.00l
compared to corresponding ffA at 5 mM glucose. (One-way ANOVA
with Bonferroni post-hoc test).
As concluded from the celi toxicity data, etevated gtucose moderately
increased apoptosis in the absence of fatty acids. Palmitate, stearate and
linoleate induced ceil death pnmarily by apoptosis ami, as for ceil death
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exarnined by trypan blue (Figure 14). fFA-induced apoptosis was strongÏy
glucose concentration dependent. The saturated FFA. palmitate and stearate.
were more potent compared to linoleate at high glucose and unlike linoleate.
were able to induce more apoptosis at intermediate (11 mM) compared to low
(5 mM) glucose. Linoleate caused significant apoptosis (30 %) only at
elevated glucose (20 mM). Oleate vas minimally toxic at 5 mM glucose and
its toxicity in terrns of apoptosis and necrosis was not increased at elevated
glucose.
The apoptosis induced by FFA at clevated glucose was further examined and
conflrmed when celis were analyzed with AnnexinV binding under
fluorescence microscopy (Figure 1$).
Glucose 5rnM Glucose 20 mM
Steaiate/2OmM Glucose
Figure 1$: Stearate at elcvated glucose levels cause phosphatidylserine
flip. INS $32/13 ceils were grown on glass coverslips placed in 6-well
plate for 48 hours, then celis were treated at 5 or 20 mM glucose in the
absence (control) or presence of 0.25 mM stearate for 24 hours. Celis were
then stained with Annexin-V and PI as described under Materials and
Methods. Annexin-V staining was visualized under fluorescence
mÏcroscopy’.
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In ceits undergoing apoptosis, phosphatidylserine (PS) which is usually
present on die limer layer of die plasma membrane flips to die outer layer and
is bound to annexin-V. Annexin-V is a phospholipid-binding protein with a
high affmity for PS. PS flip serves as a marker for apoptotic ceils. Annexin V
wiIl flot bind intact normal ceils but ceils undergoing either apoptosis or
necrosis. In necrotic ceils, leakage cari occur, thereby, Annexin V binds to PS
on the inner leaflet. Thus, to differeniate apoptosis from necrosis, ceils are
simultaneously stained wiffi annexin V and PI. Ceils undergoing apoptosis
therefore, wilJ be observed wiffi this technique to have green fluorescence
staining of die plasma membrane. The effect of fatty acid stearate was
examined using dis technique at both 5 and 20 mM glucose (Figure 1$).
As shown in figure 1$, at 20 mM glucose few celis exhibited annexin V
staining. At 20 mM glucose together widi stearate however, more celis
exhibited annexin V staining indicative ofapoptosis.
4. Palmitate at Elevated Glucose Induces Caspase-3 Activation and PARP
ckavage
To confirm that diese morphological changes were part of an apoptotic
process, we evaluated die effect of die varlous fFA on the activation of
caspase-3, a hallmark ofapoptosis (Figure 19).
None of die tested ffA significantly increased caspase-3 activity at low
glucose. Palmitate and stearate synergized wiffi high glucose to increase
caspase-3 activity by 8- and 11 -fold, respectively. Oleate did flot cause
activation of caspase-3, and linoleate, togeffier wiffi high glucose, increased
caspase 3 activity by about 4-fold.
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figure 20: PARP cleavage
induced by stearate is glucose
dependent. 1NS $32/13 celis
were grown as discussed earlier
in figure 19 treated with
stearate (0.25 mM) at different
glucose concentrations for 48
hours. Celis were harvested,
lysed and protems were
quantitated as discussed under
Materials and Methods.
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Figure 19: The action of vanous free fatty acids on caspase-3
activation is glucose.dependent. INS 832/13 celis were cuitured for 24 h
as described earlier in RPMI incubation medium at 5 or 20 mM glucose in
the absence (control) or presence of 0.4 mM palmitate (Pal), oleate (01),
linoleate (Lin) or 0.25 mM stearate (St). Ccli lysates were incubated with
the caspase-3 substrate Ac-DEVD-AFC. Fluorescence of released AFC
was measured as described in Methods. Resuits are presented as fold
increase over control and are means ± S.E. of four separate expenments. ,
P<0.05 compared to control at 5 mM glucose. P<0.05 compared to
corresponding FFA at 5 mM glucose. #, P<0.001 compared to control at
20 mM glucose. (One-way ANOVA with Bonferroni post-hoc test).
Saturated fatty acids at elevated glucose concentrations aiso caused cleavage
of poly ADP-ribose polymerase (PARP) with the formation of the 85 Kd
fragment, charactenstic ofapoptosis as shown in figure 20.
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To detennine whether mhibiting caspases could provide a means by which B
celi death mduced by elevated glucose ami fatty acids, singly or combined
could be reduced, apoptotic and necrotic events were quantitated in the
absence and presence of the pancaspase inhibitor zVAD-fMX. As expected,
z-VAD-fMK was highly effective at both inhibiting caspase-3 activation
(Figure 21) and reducing apoptosis mduced by clevated glucose alone and
elevated glucose with palmitate (figure 22A). This translated mto an
inhibition of ccli death induced by elevated glucose singly, but surprisingly,
had no effect on the very high rate of ccli death induced by high glucose and
palmitate together due to a dramatic shift from apoptosis to necrosis (Figure
22A).
‘ 160G20
F4
10-
‘—‘8
I
Cont ot Lin
Figure 21: z-VAD-FMK blocks activation of caspase-3 induced
by fFA at elevated ghicose levels. INS $32/13 celis were cultured
for 24 h as described in figure 19 at 20 mM glucose in the absence
(control) or presence of 04 mM palmitate (Pal), oleate (01), linoleate
(Lin) or 0.25 mM stearate (St) and 50 1tM z-VAD-fMK. Ccii lysates
were incubated with the caspase-3 substrate Ac-DEVD-AFC.
fluorescence of released AFC was measured as described in the
Matenals and Methods section. Data represent three different
duplicate experiments and are expressed as mean ± S.E. , P<0.01
compared to palmitate or stearate at 20 mM glucose without z-VAD
fmk. (One-way ANOVA with Bonferroni post-hoc test).
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Figure 22: Inhibition of palmïtate-induced caspase activation is coupled
with a switch to necrosis. A. NS 832/13 celts were grown in complete
RPMI medium contairnng 10 % FBS at 11 mM glucose on coverslips for
two days. They were then pre-treated with the caspase inhibitor z-VAD (50
pM) for two hours in complete RPMI medium. Medium was changed to
RPMI incubation medium containing 0.5 % BSA at 5 (G5) or 20 mM (G20)
glucose in the absence (control) or presence of 0.4 mM palmitate (Pal) and
z-VAD-fmk for 24 h. Celis were then stained with Hoechst 33342 and PI
ami viable, apoptotic (A) and necrotic (N) celis were counted using
fluorescent microscopy from five fields chosen randomly. Resuits are
expressed as percent of total ceil number. B. Results are expressed as total
celi death (sum of apoptotic and necrotic celis). Data represent four different
duplicate experiments and are expressed as mean S.E. , P<0.01
compared to palmitate at 5 mM glucose. P<0.0l compared to control at
20 mM glucose. #, P<0.001 compared to same condition without z-VAD
fmk. (One-way ANOVA with Bonfeffoni post-hoc test).
4o
20
I 0i
0
**
*
#50-A
lEI G5
G2040
— G5+zVAD-fmk
‘ G20+zVAD-fmk
53O
20
Q
10
o
A N A N
Control Palmitate
60j n
G 20
G 20+ z-V A D
j
A N A N
Co.trol Sterate
The same observation was made with stearate and linoleate at elevated
t. elea te
glucose concentrations (Figure 223).
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Altogether, this series of experiments establishes that an apoptotic pathway is
induced in INS 832/13 celis by either high glucose or some fatty acids.
Together, however, elevated glucose ami, in particular, saturated fatty acids
are markedly synergistic in this effect. In addition, glucotoxicity but flot
glucolipotoxicity, can be prevented by a caspase inhibitor (Figures 22).
5. Metabolism of Palmitate but not its Mitochondrial 8-Oxidation is
Required for Glucolipotoxicity.
Treating INS $32/13 ceils wiffi triacsin-C, an inhibitor of acyl-CoA synthase
(Noel, Antinozzi et al. 1997), blocked ceti death induced by palmitate at 20
mM glucose (Figure 23). for reasons that are unclear, triacsin C exhibited
cytotoxïcity in the absence of exogenous fFA but flot in their presence.
Perhaps in the absence of exogenous fFA, triacsin-C competes with the smalt
amount of endogenously released fFA for reactions that are limiting for
vanous essential ceif function; these processes would flot be limited by the
drug when exogenous FFA are provided. In any event, the data indicate that
CoA-estenfication of fatty acids, the first step offFA metabolism, is required
for the toxic action offatty acids at elevated glucose.
Figure 23: Palmitate must be metabohzed to
synergize with elevated glucose to induce il-ceil
death. INS $32/13 ceils were preincubated (as
described in Figure 22 for I h) with or without the
acyl-C0A synthase inhibitor triacsin C (5 jiM) and
subsequently cultured for 24 h in RPMI incubation
medium with or without Iriacsin C at 5 (G5) or 20
mM (G20) glucose in the absence or presence of
0.3 mM palmitate (Pal). Ceti death was evaluated
with trypan blue staining. Mean ± S.E. of four
determinations (two separate duplicate
experiments). , P<0001 comparcd to Pal(-),
Tnacsin(-) at 5 mM and 20 mM glucose. #,
P<0.01 compared to PaI(-), Tnacsin (+) at 20 mM
glucose. P<O.001 compared to Pat(+),
Triacsin(-) at 5 mM glucose. I# P<0.001
compared to PaI(+), Tnacsin(-) at 20 mM glucose.
(One-way ANOVA with Bonferroni post-hoc test).
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In addition the resuits show that gtucolipotoxicity is flot the resuit of an
unspecific toxic effect of FFA themselves.
Treating INS $32113 ceils with etomoxir, an inhibitor of CPT I that catalyzes
the rate-Iimitmg step of the 8-oxidation offFA, markedly amplified ceil death
(Figure 24A) and caspase-3 activation (Figure 24B) mduced by palmitate (0.3
mM) at elevated glucose. Interestingty, etomoxir atone at low glucose was flot
toxic in the absence of exogenous palmitate but allowed lipotoxicity of
palmitate at low glucose that was similar in its extent to the glucolipotoxicity
caused by the combined presence ofhigh glucose and palmitate (figure 24A).
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Figure 24: The fatty acid il-oxidation inhibitor etomour induces
palmitate toxicity at low glucose and enhances palmitate toxicity at
high glucose. A. INS $32/13 cells were preincubated as described in
figure 22 for I h with or without etomoxir (0.2 mM) and subsequently
cultured for 24 h in RPMI incubation medium at 5 (G5) or 20 mM (G20)
glucose in the absence or presence of 0.3 mM palmitate (Pal) with
etomoxir. Dead (trypan blue positive) celis were counted and reported as
percentage of total celis counted. Mean ± S.E. of three separate duplicate
experiments. B. Ceils were treated as in panel A and caspase-3 activity
was measured as descnbed in Figure 19. . Mean ± S.E. of three separate
duplicate expenments. B. Celis were treated as in panel A and caspase-3
activity was measured as described in figure 3. Mean ± S.E. of three
separate expenments. , P<O.05 compared to Pal(-), Etomoxir(-) at 5 mM
glucose control; 1 P<O.O1 compared to PaI(+), etomoxir(-) at 5mM
glucose; #, P<0.001 compared to Pal(+), Etomoxir(-) at 20 mM glucose.
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This suggests that the 8-oxidation of fatty acids is flot mvolved in the
mechanism by which palmitate induces apoptosis at elevated glucose, but
rather that glucose inhibition of fat oxidation (Prentki and Corkey 1996;
Prentki, Joly et al. 2002) is involved in this process.
6. Accumulation of Ceramide after Saturated Fatty Acid Treatment
Ceramide is a lipid signaling molecule involved in regulating key biological
processes such as celi senescence, stress responses, celi cycle arrest and
apoptosis (Hannun 1996; Hannun and Luberto 2000). Some evidence for a
role of the de novo synthesis pathway of ceramide in B-cell lipotoxicity has
been provided in the ZDF diabetic rat model (Shimabukuro, Higa et al. 199$).
Saturated fatty acids such as palmitate and stearate enter directly into the de
novo synthesis of ceramide. To gain insight into the mechanism of 8-celi
glucolipotoxicity, the ceramide content of INS $32/13 celis treated with
elevated glucose and fatty acids was measured (figure 25). Elevated glucose
or the various fFA (palmitate, stearate, oleate and linoleate) alone did not
alter the ceramide content. The ceramide level of 1NS 832/13 cells, however,
increased 2-3 times in palmitate- and stearate-treated celis at high glucose
compared to low glucose (Figure 25).
oFigure 25: Elevated glucose plus saturated E
fatty acids cause ceramide accumulation in o 300’INS 832/13 cells. Ceils were cultured for 24 h
as described earlier in the absence or presence ‘‘ -
of 0.4 mM palmitate (Pal), oleate (01), linoleate
(Lin) or 0.25 mM stearate (St) at 5 (G5) and 20
mM (G20) glucose. The cellular ceramide
content was determined using the diacylglycerol 150
kinase assay and nonualized to total lipid
phosphate content (as described under Materials im
and Methods). Means ± S.E. of five different j
duplicate expenments. , P<0.001 compared to 50
control at 5 and 20 mM glucose P<0.001
compared to Pal or St at 5mM glucose. (One
way ANOVA with Bonferroni post-hoc test).
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figure 26: The ceramide synthase inhibitors fumonisin Bi (FB1)
and myriocin do not block the risc in cellular ceramide caused by
the combined presence of elcvated glucose and palmitate. Ceils were
pre-incubated with (A) FBI (50 jiM) or (B) myriocin (20 1iM) for 2 h as
described earlier followed by another incubation in RPMI incubation
mediwu and 0.5 % BSA at 5 (G5) or 20 mM (G20) glucose in the
absence (control) or presence of 0.4 mM pahuitate (Pal) and FBI or
myriocin for 24 h. Cellular ceramide content was measured as in figure
25. Means ± S.E. of three different duplicate experunents. , P<0.001
compared to Pal(-), FB1(-) or myriocin (-) at 5 and 20 mM glucose. **,
P<0.001 compared to Pal at 5mM glucose. (One-way ANOVA with
Bonferroni post-hoc test).
The data are compatible wiffi the possibility that ceramide might be involved
in signaling apoptosis induced by saturated fatty acids at elevated glucose.
However, in 1NS $32/13 ceils, the de novo pathway of ceramide synthesis
b further investigate the mechanism of ceramide accumulation, we treated
1NS 532/13 cells wiffi two inhibitors (myriocin and fumonisin FB1) ofthe de
novo pathway of ceramide which inhibit senne palmitoyltransferase (SPT)
and ceramide synthase, respectively. Both myriocin and fumonisin Bi did flot
btock ceramide accumulation (figure 26) or ceil death (Figure 27) induced by
the combined presence of elevated glucose and palmitate.
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does flot appear to be mvolved either in ffie mechanism promoting ceramide
accumulation or in ccli death induced by glucolipotoxicity.
A **701 *
Mytiodu- + -
figure 27: The ceramide synthase inhibitors fumonisin Bi (FB1)
and myriocin do flot block palmitate induced cdl death at elevated
and patmitate. Celis were pre-incubated with (A) fB1 (50 iiM) or (B)
myriocin (20 jiiM) for 2 h (as descnbed in figure 26) followed by
another incubation in RPMI incubation medium with 0.5 % BSA at 5
(G5) or 20 mlvi (G20) glucose in the absence (control) or presence of
0.4 mM palmitate (Pal), fB1 or myriocin for 24 h. Adherent and
floating celis were then coliected, combined and stained with trypan
blue to measure ccli death. Resuits are expressed as percent of total
ccli number. Means ± S.E. ofthree different duplicate experiments. ,
P<0.001 compared to Pal(-), FBI(-) or myriocin (-) at 5 and 20 mM
glucose. P<0.001 compared to Pal at 5mM glucose. (One-way
ANOVA with Bonferroni post-hoc test).
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CHAFTER 4: DISCUSSION
In this study, we demonsfrated for the first time a marked synergistic effect of
high glucose and saturated ffA on mducing ceil death by apoptosis in INS
832/13 8-cells (Figures 13, 14 and 17). Elevated glucose and fFA together
were much more toxic than eiffier of these factors alone. In addition, we found
differential effects of the various fatty acids tested at high glucose, with
palmitate (saturated FFA) dramatically havmg the most toxicity, Imoleate
(jolyunsaturated FfA) havmg modest toxicity and oleate (monounsaturated
FfA) having poor or no toxicity (Figures 13 and 14). Thus, for saturated fatty
acids in particular, the results are consistent with the glucolipotoxicity
hypoffiesis (Pren&i and Corkey 1996; Prentki, Roduit et al. 2001; Prentki,
Joly et at. 2002), amI provide strong support for the concept that this process
is implicated in the progressive Ioss of 8-ceil mass by apoptosis which is
involved in the pathogenesis of type 2 diabetes (Butier, Janson et al. 2003).
As reviewed recently (Prentki, Joly et al. 2002), glucolipotoxicity may also
contribute to the etiology of type 1 diabetes and has implications for
transplanted type I diabetic patients. Another component of the
glucolipotoxicity hypothesis flot addressed in this study is that which causes
8-celi dysfunction. In support of this component, Poitout and colt.
(Jacqueminet, Briaud et al. 2000) showed in rat islets that 72 h of culture in
the presence of palmitate at low glucose did not affect insulin mRNA and
insulin biosynthesis, but at high glucose these parameters were reduced.
Similarly, the palmitate effect on decreasing IDX-1 expression, a 8-celi
differentiation factor, was shown to be glucose dependent (Gremlich, Bonny
et al. 1997).
After correcting for the difference in BSA concentration used in the media of
our expenments (0.5%), and the much higher BSA concentration of human
plasma (‘—3.5 %), the unbound FFA concentrations we used were in the order
of 5-6 fold higher than is usually present in the plasma of subjects at high nsk
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ofdiabetes (Stefan, Stumvoll et al. 2003). However, our media did flot contain
trigtycende in VLDL particles, the fatty acids of which are available to islets
in vivo via Jipoprotem lipase (LPL) which lias been showu to be present and
active in islet tissue (Cruz, Kwon et al. 2001). furthermore, triglyceride levels
in diabetic plasma and in subjects at nsk of type 2 diabetes are commonly
elevated above 2 mM. Hence, the actual supply offFA to the 1NS cells in our
experiments (from media fFA only) compared to islets of subjects at nsk of
type 2 diabetes (from plasma FFA and triglycende) may flot be very different.
Hoechst and PI staining, Annexin-V bindmg, PARP cleavage and caspase-3
expenments showed that both apoptosis and necrosis are iniplicated in fFA
induced cytotoxicity, however apoptosis is the major pathway leading to B
ccli death caused by elevated glucose and FfA singly or combined (figures
16-20). When caspase-3 activation was inhibited using the pan-caspase
inhibitor z-VAD-ftnk (figure 21), apoptosis mduced by glucose was btocked;
however, in the presence of palmitate at high glucose levels, z-VAD-fmk
caused a switch from apoptosis to necrosis (Figure 22). This bas been
observed earlier in other systems (Lemaire, Andreau et al. 1998; Sane and
Bertrand 1999). Ibis suggests that glucolipotoxicity exerts a vely severe insuit
to the 8-ceil in comparison to glucotoxicity that can be halted by an
antiapoptotic agent.
The mechanism of FFA-induced apoptosis is not wetI understood. However,
according to the glucolipotoxicity hypothesis (Prentki, ioiy et al. 2002) it is
predicted that, at elevated glucose, LC-CoA derived from simultaneously
elevated ffA wilI accumulate due to the inhibitory effect of the glucose on
lipid detoxification via 13-oxidation. This resuits in increased LC-CoA
partitioning towards toxic cellular processes either directly or indirectly via
acylation andlor esterification products. In support of this concept, treating
ceils with the fatty acyl-CoA synthetase (ACS) inhibitor friacsin C
demonstrated, in accordance with previous resuits in ZDF rat islets
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(Shimabukuro, Higa et al. 199$), that apoptosis mduced by saturated fatty
acids is flot caused by the FFA themselves, but by LC-CoA andlor metabolites
denved from them (Figure 23). Furthermore, etomoxir, an inhibitor of CPT I
the rate-limitmg enzyme in the 8-oxidation of ffA, enhanced ceil death and
caspase-3 activation at both low and elevated glucose levels suggesting that
the toxicity of fatty acids at elevated glucose is flot mediated via their
oxidation (Figure 24). Interestmgly, etomoxir atlowed Iipotoxicity of
palmitate at low glucose at a level equivalent to the glucolipotoxicity caused
by the combmation of high glucose and palmitate. Also consistent with the
view that glucose-mduced inhibition of fat oxidation is important in the
mechanism whereby glucose and FFA synergize to cause -cell death, long
term exposure offi-celis to glucose causes sustained accumulation ofthe CPT
I inhibitor matonyl-CoA (Prentki, Vischer et al. 1992), chronically suppresses
fat oxidation (Roche, Farfan et al. 1998) and stimulates fat esterification
processes (Roche, Farfari et al. 199$). In the 8-ceil, we (Prentki, Vïscher et al.
1992) and others (Jacqueminet, Bnaud et al. 2000) have also reported that
elevated glucose and pahuitate or oleate synergize in promoting lipid
esterification with increases particularly in triglycende esterification and
deposition.
With respect to the triacsin C resuits, there are at least five isoforms of ACS
with different tissue distribution, subcellular Iocalization, subsfrate preference
and regulatory mechanisms. Only two of these five ACS are inhibited by
triacsin C (Kim, Lewin et al. 2001; Lewin, Kim et al. 200!; Coleman, Lewin
et al. 2002). The mitochondnal membrane bound ACS-5, an isoform thought
to channel LC-CoA to CPT I, is flot sensitive to triacsin C (Coleman, Lewin et
al. 2002). Thus, in agreement with this fmding, it is possible that tnacsin C
inhibited only the LC-CoA pool which is channeled for esterification.
It has been proposed, using ZDf rat islets as a mode! (Shimabukuro, Higa et
al. 199$), that FFA mediate apoptosis of B-cells via the de novo synthesis of
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ceramide. Our resuits clearly show that saturated FfA caused an mcrease in
ceramide accumulation only at elevated glucose (20 mM) (Figure 25). This
suggests that ceramide accumulation could be implicated in ffA-induced
apoptosis at high glucose. Two inhibitors of die de novo pathway of ceramide
synthesis, however, neither blocked ceil death nor ceramide accumulation
which suggest that de novo synthesis of ceramide is flot involved in fFA
induced apoptosis at elevated glucose levets in INS 832/13 cells. This is partly
in contrast with other studies in which ceramide synthesis inhibitors reduced
apoptosis of B-cell death (Shimabukuro, Higa et al. 1998; Maedler, Spinas et
al. 2001; Lupi, Dotta et al. 2002). The difference between the other studies
and our resuits could be attributed to differences in the concentration and
composition of fatty acids used and to differences in experimental systems.
However, we cannot exciude the possibility that the inhibitors did flot work in
our system. We feet this is unlikely since die same inhibitor preparations gave
positive resuits in another celi system in our hands (Hardy S, Prendd M, JBC
in Press). Nevcrtheless, we will further study these inhibitors and diese
experùnents wiII include a positive control in 1NS 832/13 celis. Our resuits do
flot underscore die importance of ceramide in FFA induced apoptosis,
however other padiways of ceramide generation shoutd be examined such as
the sphingomyelin pathway (Liu, Obeid et al. 1997).
The minimal toxicity of oleate, an abundant FFA in serum, is particularly
interesting. Unsaturated fatty acids such as oleate and palmitoleate have been
shown in some cellular systems to have either no effect on apoptosis (de
Vries, Vork et al. 1997; Maedler, Spinas et al. 2001), or even to protect from
palmitate-induced apoptosis (de Vries, Vork et aI. 1997; Hardy, Langetier et
al. 2000; MacUler, Spinas et al. 2001). The difference between palmitate and
oleate on 8-celi cytotoxicity could be attributed to differences in metabolism
of die fatty acids, in particular the make up ofdie phospholipid pool. Thus, die
enrichment of phospholipids by saturated fFA lowers membrane fluidity,
impairing various membrane functions (Innis and Clandinin 1981; Stubbs and
64
Smith 1990). Reduced cardiolipin synthesis is another possibility as palmitate
lias been shown to decrease the synthesis of cardiolipm in cardiomyocytes
(Ostrander, Sparagna et aL 2001) and the breast cancer ceils MDA-MB231 (S.
Hardy ami M.P., JBC in press). The phospholipid cardiolipm binds
cytochrome C in the mitochondrion which prevents the release of cytochrome
C into the cytoplasm, this release being an important event in the apoptotic
process (Zou, Li et ai. 1999). We previously showed that oleate activates PI-3
kinase in MDA-MB23 1 celfs ami promotes ceil proliferation, whereas
palmitate had opposite effects (Hardy, Langelier et al. 2000). Thus, it would
be of interest to determine whether patmitate also reduces PI-3 kinase activity
in the 8-ceil considering that this enzyme plays a cntical rote in the control of
ceil growth and apoptosis (Cantley 2002). In any event, the differential effects
of saturated versus unsaturated ffA on 8-ceil apoptosis is of interest from a
nutritional stand point and provides a plausible explanation for various
epidemiological and dietary intervention studies which have consistently leU
to the recommendation of a low saturated/high monounsaturated fat diet for
type 2 diabetes prevention (Thanopoulou, Karamanos et aI. 2003).
The experiments described in this study were alt performed in an
immortalized pancreatic f3-cell me and we clearly understand that there are
great limitations in extrapolating the findings to human islets. In this respect,
we have afready started performing experiments on dissociated human islet
cetis ex-vivo and on rat islet tissue in order to verify the ceil une resuits. The
initial islet resuits are clearly consistent with the fmdings of the INS celi
expenments.
The clinical importance of the islet B-ceIl glucolipotoxicity concept deserves
further consideration taking into account the resuits of the current study.
Continuai loss of islet 13-ceil mass is almost certainly involved in the
progressive deterioration in insulin secretion which occurs through both the
early (e.g. conversion from impaired glucose tolerance (IGT) to diabetes) and
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late stages of type 2 diabetes (e.g. secondaiy failure of oral hypoglycemic
agents) (Butier, Janson et al. 2003; Kahn 2003). Islet B-cell loss is also a
major problem both pre- and post-transplantation in the islet replacement
programs for type 1 diabetes (Contreras, Bilbao et aI. 2001). Aggressive
strategies to I imit 6-ceti loss, therefore, need to be developed and, it follows
from this study, that these strategies should mclude the avoidance of
glucolipotoxicity. Whereas reduction in glucolipotoxicity may have been a
mechanism involved in the success of lifestyle modification with weight loss
in some studies of type 2 diabetes prevention (Pan, Li et al. 1997; Tuomilehto,
Lindstrom et aI. 2001; Knowler, Barreil-Connor et al. 2002), the successful
STOP-MDDM trial (Chiasson, Josse et aI. 2002) is more directly supportive
of using approaches to limit glucolipotoxicity. Thus, in this study (Chiasson,
Josse et aI. 2002), acarbose, which primarily acts by reduction of postprandial
glucose but can also reduce postprandial lipid levels (Kado, Murakami et al.
199$), was used and reduced conversion to diabetes. Our findings also point
to two further approaches that show potential for reducing gfucolipotoxicity.
The first is dietary substitution of saturated with monounsaturated fatty acids.
The second is using pharmacological tools to activate -ceIl fatty acid
oxidation such as activators of AMP-activated protein kinase (AMPK).
Preliminaiy experiments performed in our Iaboratory using metformin and 5-
amino-imidazole-4-carboxamide- 1 -B-D-ribofuranoside (MCAR), both
pharmacological activators of AMPK, showed protection from
glucolipotoxicity. 0f relevance to this latter approach, metfonnin bas also
been shown to reduce progression from IGT to diabetes (Knowler, Barrett
Connor et al. 2002).
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Future Directions
To further test the hypothesis that glucose-denved malonyl-CoA and elevated
cytosolic long chain acyl-CoA esters act as proapoptotic metabolic signais
mediatmg the actions of elevated glucose and ffA on 13-ceil death,
experiments targetmg the maionyl-CoAICPT I interaction are potentially very
useful. Pharmacologic and molecular biology tools provide two approaches
which could help in establishing whether increased fat estenfication and
reduced 3-oxidation are implicated in -ceiI glucolipotoxicity. The correlation
of malonyl-CoA and LC-CoA determinations with apoptosis measurements
will also be instrumental in determining whether malonyl-CoA and FACoA
are proapoptotic metabolic signais.
To this end, we plan to alter the expression level of enzymes invoived in the
regulation of malonyl-CoA levels and the partitioning of lipids in the -ce11 by
using both a recombinant adenovirus approach and post transcnptional gene
silencing (PTGS) by small interference RNAi (siRNA). In support of this
approach, a recent report showed that inhibitors offAS which caused a nse in
malonyl-CoA, induced apoptosis of human breast cancer celis. Apoptosis in
these celis was rescued by inhibitors of ACC which lowered malonyl-CoA
levels (Pizer, Thupari et al. 2000).
1. Two enzymes tightly regulate the levels of malonyl-CoA, acetyl-CoA
carboxylase (ACC) and malonyl-CoA decarboxylase (MCD).
a) ACC plays a unique role in the production of malonyl-CoA, since it is the
only enzyme which produces malonyi-CoA. Glucose induced increases in
ACC activity, together with increased substrate supply for glucose driven
anaplerosis result in production of malonyl-CoA, a powerful inhibitor of CPT
I. Glucose is involved in both short and long tenu activation of ACC. Short
tenu activation is achieved by dephosphorylation of ACC (Louis ami Witters
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1992; Zhang and Kim 1995) and long term activation is accomplished by
means of the activation of gene expression via PI! promoter of ACC (Brun,
Roche et al. 1993).
ACC will be targeted usmg siRNA. In this model, malonyl-CoA level should
decrease and thus CPT I should be de-inhibited at elevated glucose levels. We
expect that apoptosis mduced by ffA at elevated glucose levels will thus
decrease.
b) MCD lias bcen proposed to regulate the levels of malonyl-CoA at teast in
non-lipogenic tissues where FAS level is low (Voilley, Roduit et al. 1999).
MCD catalyzes the decarboxylation of malonyl-CoA back mto acetyl-CoA.
Our laboratory cloned the rat MCD cDNA from an msulin-secretmg
pancreatic -cell une tINS-1) (Voilley, Roduit et al. 1999). Evidence
indicatmg the importance of MCD in regulating malonyl-CoA levels and in
supporting the glucolipotoxicity concept came from experiments done by our
group (Roduit R, Pren&i M, submitted). The enzyme was expressed in a
tetracycline regulatable mamier in INS $32/13 celis and in rat islets. MCD
activity was increased more than five fold resulting in markedly reduced
malonyi-CoA content under both low and high glucose conditions. This was
associated with altered lipid partitioning in tenus of glucose induced lipid
estenfication processes. The esterfication products phospholipids,
diacylglycerol, and triacylglycerol were ail significantly decreased under
MCD overexpression at conditions of elevated glucose levels. The data from
this study, confirm the presence of important links between ffie nutrient
coupling factor malonyl-CoA and the partitioning of fatty acids to
estenfication products.
This model of MCD overexpression wilI be extended to include the role for
glucose-derived malonyl-CoA and exogenous FFA via LC-CoA on P-cell
toxicity. In this respect, MCD will be targeted by two approaches.
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I- MCD will be overexpressed usmg an adenovirus in a tetracycline
regutatable manner and FfA induced -cell toxicity at elevated glucose levels
will be tested as well as lipid partitioning in terms of fatty acid esterification
and oxidation. We expect that under these conditions, toxicity mduced by
ffA at elevated glucose levels will decrease since glucose denved malonyl
CoA level will be Iowered by MCD overexpression such that CPT I will be
de-inhibited. Thus, we expect that FfA toxicity will be decreased because
these are channeled towards oxidation away from esterification.
ii- Another way to target MCD is via PTGS usmg sRNAi. In this method, the
MCD gene wilI be silenced post transcriptionally such that malonyl-CoA
should accumulate to higher levels at elevated glucose levels. This will cause
inhibition of CPT I such that LC-CoA wilt accumulate and will be channeled
to esterifcation. In this model, we expect that toxicity induced by FFA at
elevated glucose concentrations will further increase.
In both models, malonyl-CoA levels wilt be measured in order to correlate the
levels oftoxicity with malonyl-CoA levels.
2- CPT I, is a third enzyme we believe lias a key role in glucolipotoxicity
which we wish to target. CPT I is the rate limiting enzyme in mitochondnal (3-
oxidation of fatty acids. A mutant enzyme which is active but insensitive to
malonyl-CoA inhibition will be overexpressed using an adenoviral construct.
We expect that overexpressing this mutant CPT I wiIl prevent malonyl-CoA
inhibition of CPT I activity thus altering the partitioning of LC-CoA ftom
estenfication to mitochondrial (3-oxidation pafticularly in situations of high
glucose.
We hypothesize that increased CPT I activity at high glucose wiIl cause
increased oxidation of FfA. Thus, this detoxification step might rescue the (3-
celi from glucolipotoxicity.
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3-In vivo studies are important to confirm ffie data obtained in vitro. Studies
on two different animal models could be carned out:
a) The Zucker fatty (ZF) rats. These rats have elevated levels of fFA but
normal glucose levels. Inftismg these animais with glucose to elevate plasma
concentrations (saline for conirol) for a period of time will be useful to
monitor islet -celI toxicity. Apoptotic assays could be performed on islets of
these animais to measure 3-cell toxicity and fatty acid-g]ucose synergy.
b) A second moUd wouid utilize high fat feedmg (diets high in saturated vs
monounsaturated fat) to rats in addition to infusing glucose to elevate plasma
concentrations (saline for control) with heparin (which stimulates lipoprotein
Lipase (LPL) thus mcreasmg the levels of saturated or monounsaturated FFA).
We believe that these experiments will conftrm the process of
glucolipotoxicity in vivo. Recently, our data and the glucolipotoxicity
hypothesis were supported by a clinical study camed out on Pima Indians
(Stefan, Stumvoll et al. 2003). This study showed detenoration in insuim
secretion in subjects with the combmation of elevated glucose and fatty acids
but no deterioration if only glucose alone or fatty acids alone were eievated.
Other Potential targets in the control of glucolipotoxicty include PPAR-a,
AMPKandGLPI.
4- PPAR-u and AMPK are other potential targets in the control of
glucolipotoxicity. As mentioned earlier, glucose at high concentrations
downregulates PPAR-a expression, which intum downregulates ACO and
UCP-2 expression. Thus, with hyperglycemia (post prandial or chronic), the 3
pathways of fat oxidation are reduced because of:
a) a sustained elevation in malonyl-CoA which inhibits CPT I, the key
enzyme in the mitochondrial -oxidation of FA,
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b) a reduction in PPAR-Œ expression which causes a downregulation in acyl
CoA oxidase (ACO) which is important for peroxisomal -oxidation and
downregulation of uncoupler protein 2 (UCP2), which is important for
mitochondrial uncoupled oxidation.
Experiments targeting PPAR-a and AMPK expression and acfivity, therefore
are important in exploring the importance of Iipid partitioning in
glucolipotoxicity. Some such experiments are currently being carned ont in
our laboratory which include the use of:
I- MCAR which activates AMPK;
ii- Metformin which also activates AMPK, has in addition antioxidant
properties;
iii- AMPK dominant negative and AMPK constitutively active adenoviruses.
5- The peptide glucagon like peptide 1 (GLP 1) is an incretin secreted from
intestinal ceils which has also been demonstrated to have an antiapoptotic
activity in glucolipotoxicity models in our Iaboratory. This is another area
which warrants fiirther investigation.
The following scheme illustrates potential strategies to fin-ther understand the
glucolipotoxicity concept (figure 2$).
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Figure 2$: Planned experimentat approaches to further
investigate the role of malonyt-CoA and Iipid partitioning in
glucolipotoxicity. Molecular biological and pharmacological tools
will be utilized to either mcrease or decrease malonyl-CoA. In
addition, tools wilI be used to eithcr mcrease fatty acid -oxidation
to detoxify LC-CoA or increase the availability of LC-CoA for
toxicity (sec text for discussion).
We feel that ffie concept of altered lipid partitioning together, with the
experiments mentioned above are, instrumental in addressmg
glucolipotoxicity (Figure 28). This is because of the data we and others have
accumulated showmg that elevated levels of glucose and FFA synergize in
causmg TG deposition and apoptosis in -cell. We believe that the data
afready obtained and presented here in addition to the proposed expenments
will have important implications for prevention and treatment of type 2
diabetes.
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